200,000+ products from a single source!
sales@angenechem.com
Home > Other Building Blocks > 25812-30-0
25812-30-0 | 5-(2,5-Dimethylphenoxy)-2,2-dimethylpentanoic acid
CAS No: 25812-30-0 Catalog No: AG0034YR MDL No:MFCD00079335
Product Description
Catalog Number:
AG0034YR
Chemical Name:
5-(2,5-Dimethylphenoxy)-2,2-dimethylpentanoic acid
CAS Number:
25812-30-0
Molecular Formula:
C15H22O3
Molecular Weight:
250.3334
MDL Number:
MFCD00079335
IUPAC Name:
5-(2,5-dimethylphenoxy)-2,2-dimethylpentanoic acid
InChI:
InChI=1S/C15H22O3/c1-11-6-7-12(2)13(10-11)18-9-5-8-15(3,4)14(16)17/h6-7,10H,5,8-9H2,1-4H3,(H,16,17)
InChI Key:
HEMJJKBWTPKOJG-UHFFFAOYSA-N
SMILES:
Cc1ccc(c(c1)OCCCC(C(=O)O)(C)C)C
EC Number:
247-280-2
UNII:
Q8X02027X3
NSC Number:
757024
Properties
Complexity:
273
Compound Is Canonicalized:
Yes
Covalently-Bonded Unit Count:
1
Defined Atom Stereocenter Count:
0
Defined Bond Stereocenter Count:
0
Exact Mass:
250.157g/mol
Formal Charge:
0
Heavy Atom Count:
18
Hydrogen Bond Acceptor Count:
3
Hydrogen Bond Donor Count:
1
Isotope Atom Count:
0
Molecular Weight:
250.338g/mol
Monoisotopic Mass:
250.157g/mol
Rotatable Bond Count:
6
Topological Polar Surface Area:
46.5A^2
Undefined Atom Stereocenter Count:
0
Undefined Bond Stereocenter Count:
0
XLogP3:
3.8
Literature
| Title | Journal |
|---|---|
| Expression of cytochrome P450 epoxygenases and soluble epoxide hydrolase is regulated by hypolipidemic drugs in dose-dependent manner. | Toxicology and applied pharmacology 20180915 |
| Inferring transcription factor activity from microarray data reveals novel targets for toxicological investigations. | Toxicology 20170815 |
| Discriminating between adaptive and carcinogenic liver hypertrophy in rat studies using logistic ridge regression analysis of toxicogenomic data: The mode of action and predictive models. | Toxicology and applied pharmacology 20170301 |
| New brominated flame retardants and their metabolites as activators of the pregnane X receptor. | Toxicology letters 20160930 |
| Cytochrome P450 inhibition potential of new psychoactive substances of the tryptamine class. | Toxicology letters 20160122 |
| Transcriptome analyses demonstrate that Peroxisome Proliferator-Activated Receptor α (PPARα) activity of an ultraviolet absorber, 2-(2'-hydroxy-3',5'-di-tert-butylphenyl)benzotriazole, as possible mechanism of their toxicity and the gender differences. | The Journal of toxicological sciences 20160101 |
| Comparative gene and protein expression analyses of a panel of cytokines in acute and chronic drug-induced liver injury in rats. | Toxicology 20141003 |
| Interaction of environmental contaminants with zebrafish organic anion transporting polypeptide, Oatp1d1 (Slco1d1). | Toxicology and applied pharmacology 20141001 |
| Gemfibrozil disrupts lysophosphatidylcholine and bile acid homeostasis via PPARα and its relevance to hepatotoxicity. | Archives of toxicology 20140401 |
| Genomic models of short-term exposure accurately predict long-term chemical carcinogenicity and identify putative mechanisms of action. | PloS one 20140101 |
| Development of surrogate correlation models to predict trace organic contaminant oxidation and microbial inactivation during ozonation. | Water research 20121201 |
| Occurrence of pharmaceutical compounds in wastewater and sludge from wastewater treatment plants: removal and ecotoxicological impact of wastewater discharges and sludge disposal. | Journal of hazardous materials 20121115 |
| Effects of gemfibrozil on lipid metabolism, steroidogenesis, and reproduction in the fathead minnow (Pimephales promelas). | Environmental toxicology and chemistry 20121101 |
| Optimization of solid phase microextraction for non-lethal in vivo determination of selected pharmaceuticals in fish muscle using liquid chromatography-mass spectrometry. | Journal of chromatography. A 20121026 |
| Environmental optimization of continuous flow ozonation for urban wastewater reclamation. | The Science of the total environment 20121015 |
| The role of microbial adaptation and biodegradable dissolved organic carbon on the attenuation of trace organic chemicals during groundwater recharge. | The Science of the total environment 20121015 |
| Gemfibrozil, a lipid-lowering drug, increases myelin genes in human oligodendrocytes via peroxisome proliferator-activated receptor-β. | The Journal of biological chemistry 20121005 |
| Protective effects of peroxisome proliferator-activated receptor agonists on human podocytes: proposed mechanisms of action. | British journal of pharmacology 20121001 |
| Physiologically based modeling of pravastatin transporter-mediated hepatobiliary disposition and drug-drug interactions. | Pharmaceutical research 20121001 |
| Effects of effluent organic matter characteristics on the removal of bulk organic matter and selected pharmaceutically active compounds during managed aquifer recharge: Column study. | Journal of contaminant hydrology 20121001 |
| Managing the underestimated risk of statin-associated myopathy. | International journal of cardiology 20120906 |
| Use of fibrates in clinical practice: Queensland Lipid Group consensus recommendations. | International journal of evidence-based healthcare 20120901 |
| Prediction of the in vivo OATP1B1-mediated drug-drug interaction potential of an investigational drug against a range of statins. | European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences 20120830 |
| Gemfibrozil, a lipid-lowering drug, induces suppressor of cytokine signaling 3 in glial cells: implications for neurodegenerative disorders. | The Journal of biological chemistry 20120803 |
| Gemfibrozil, a lipid lowering drug, inhibits the activation of primary human microglia via peroxisome proliferator-activated receptor β. | Neurochemical research 20120801 |
| Effect of gemfibrozil on the metabolism of brivaracetam in vitro and in human subjects. | Drug metabolism and disposition: the biological fate of chemicals 20120801 |
| The development, characterization, and application of an OATP1B1 inhibition assay in drug discovery. | Drug metabolism and disposition: the biological fate of chemicals 20120801 |
| Distribution and temporal evolution of pharmaceutically active compounds alongside sewage sludge treatment. Risk assessment of sludge application onto soils. | Journal of environmental management 20120715 |
| Design and optimization of self-nanoemulsifying drug delivery systems (SNEDDS) for enhanced dissolution of gemfibrozil. | International journal of pharmaceutics 20120715 |
| Gemfibrozil, a lipid-lowering drug, upregulates IL-1 receptor antagonist in mouse cortical neurons: implications for neuronal self-defense. | Journal of immunology (Baltimore, Md. : 1950) 20120715 |
| Persistent use of against-label statin-fibrate combinations from 2003-2009 despite United States Food and Drug Administration dose restrictions. | Pharmacotherapy 20120701 |
| Mechanism-based inactivation (MBI) of cytochrome P450 enzymes: structure-activity relationships and discovery strategies to mitigate drug-drug interaction risks. | Journal of medicinal chemistry 20120614 |
| In vitro antimalarial activity and drug interactions of fenofibric acid. | Antimicrobial agents and chemotherapy 20120601 |
| Evaluating pharmaceuticals and caffeine as indicators of fecal contamination in drinking water sources of the Greater Montreal region. | Chemosphere 20120601 |
| A review of time courses and predictors of lipid changes with fenofibric acid-statin combination. | Cardiovascular drugs and therapy 20120601 |
| HDL cholesterol--how do I raise my patients good cholesterol? | JPMA. The Journal of the Pakistan Medical Association 20120601 |
| Classification of inhibitors of hepatic organic anion transporting polypeptides (OATPs): influence of protein expression on drug-drug interactions. | Journal of medicinal chemistry 20120524 |
| Protective effect of T. violacea rhizome extract against hypercholesterolemia-induced oxidative stress in Wistar rats. | Molecules (Basel, Switzerland) 20120521 |
| Analytical and biological characterization of halogenated gemfibrozil produced through chlorination of wastewater. | Environmental science & technology 20120515 |
| Deletion of GPIHBP1 causing severe chylomicronemia. | Journal of inherited metabolic disease 20120501 |
| Pharmacokinetic drug interaction between gemfibrozil and sitagliptin in healthy Indian male volunteers. | European journal of clinical pharmacology 20120501 |
| Biological removal of pharmaceuticals and personal care products during laboratory soil aquifer treatment simulation with different primary substrate concentrations. | Water research 20120501 |
| Occurrence and persistence of organic emerging contaminants and priority pollutants in five sewage treatment plants of Spain: two years pilot survey monitoring. | Environmental pollution (Barking, Essex : 1987) 20120501 |
| Gemfibrozil is a strong inactivator of CYP2C8 in very small multiple doses. | Clinical pharmacology and therapeutics 20120501 |
| Occurrence and removal of pharmaceuticals in wastewater treatment plants at the Spanish Mediterranean area of Valencia. | Chemosphere 20120401 |
| Characterization of in vitro glucuronidation clearance of a range of drugs in human kidney microsomes: comparison with liver and intestinal glucuronidation and impact of albumin. | Drug metabolism and disposition: the biological fate of chemicals 20120401 |
| Determination of pharmaceuticals and antiseptics in water by solid-phase extraction and gas chromatography/mass spectrometry: analysis via pentafluorobenzylation and stable isotope dilution. | Analytical and bioanalytical chemistry 20120401 |
| Indole-based fibrates as potential hypolipidemic and antiobesity agents. | Journal of medicinal chemistry 20120322 |
| Suspended biofilm carrier and activated sludge removal of acidic pharmaceuticals. | Water research 20120315 |
| Formulation of poorly water-soluble Gemfibrozil applying power ultrasound. | Ultrasonics sonochemistry 20120301 |
| In vitro inhibition of cytochrome P450-mediated reactions by gemfibrozil, erythromycin, ciprofloxacin and fluoxetine in fish liver microsomes. | Aquatic toxicology (Amsterdam, Netherlands) 20120301 |
| Occurrence, fate, and persistence of gemfibrozil in water and soil. | Environmental toxicology and chemistry 20120301 |
| Mitochondrial oxidative stress alters a pathway in Caenorhabditis elegans strongly resembling that of bile acid biosynthesis and secretion in vertebrates. | PLoS genetics 20120301 |
| Antihypercholesterolaemic influence of dietary tender cluster beans (Cyamopsis tetragonoloba) in cholesterol fed rats. | The Indian journal of medical research 20120301 |
| Relationship between paraoxonase and homocysteine: crossroads of oxidative diseases. | Archives of medical science : AMS 20120227 |
| CYP2C8 but not CYP3A4 is important in the pharmacokinetics of montelukast. | British journal of clinical pharmacology 20120201 |
| In vitro and in silico strategies to identify OATP1B1 inhibitors and predict clinical drug-drug interactions. | Pharmaceutical research 20120201 |
| Human UDP-glucuronosyltransferase isoforms involved in haloperidol glucuronidation and quantitative estimation of their contribution. | Drug metabolism and disposition: the biological fate of chemicals 20120201 |
| Effects of Fenton treatment on the properties of effluent organic matter and their relationships with the degradation of pharmaceuticals and personal care products. | Water research 20120201 |
| Hypertriglyceridemia-induced acute pancreatitis treated with insulin and heparin. | American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists 20120201 |
| The cardiovascular effects of peroxisome proliferator-activated receptor agonists. | The American journal of medicine 20120201 |
| The prevalence, awareness and treatment of high low density lipoprotein-cholesterol in korean adults without coronary heart diseases - the third Korea national health and nutrition examination survey, 2005 -. | Korean circulation journal 20120201 |
| Analysis of endocrine disrupting compounds, pharmaceuticals and personal care products in sewage sludge by gas chromatography-mass spectrometry. | Talanta 20120130 |
| Effect of dietary fatty acid composition on food intake, triglycerides, and hypothalamic peptides. | Regulatory peptides 20120110 |
| DSC, X-ray and FTIR studies of a gemfibrozil/dimethyl-β-cyclodextrin inclusion complex produced by co-grinding. | Journal of pharmaceutical and biomedical analysis 20120105 |
| Genotoxic effects in fish induced by pharmacological agents present in the sewage of some Italian water-treatment plants. | Environmental toxicology 20120101 |
| Occurrence of pharmaceutical compounds in wastewater process streams in Dublin, Ireland. | Environmental monitoring and assessment 20120101 |
| A role for peroxisome proliferator-activated receptors in the immunopathology of schistosomiasis? | PPAR research 20120101 |
| Hypertriglyceridemia, Metabolic Syndrome, and Cardiovascular Disease in HIV-Infected Patients: Effects of Antiretroviral Therapy and Adipose Tissue Distribution. | International journal of vascular medicine 20120101 |
| Toxicity of mixtures of perfluorooctane sulphonic acid with chlorinated chemicals and lipid regulators. | Chemosphere 20120101 |
| Development of a bar adsorptive micro-extraction-large-volume injection-gas chromatography-mass spectrometric method for pharmaceuticals and personal care products in environmental water matrices. | Analytical and bioanalytical chemistry 20120101 |
| Impact of the counterion on the solubility and physicochemical properties of salts of carboxylic acid drugs. | Drug development and industrial pharmacy 20120101 |
| Is RORγ a therapeutic target for treating Mycobacterium tuberculosis infections? | Tuberculosis (Edinburgh, Scotland) 20120101 |
| Nuclear receptors in nonalcoholic Fatty liver disease. | Journal of lipids 20120101 |
| Current status of the immunomodulation and immunomediated therapeutic strategies for multiple sclerosis. | Clinical & developmental immunology 20120101 |
| Indicators of the atherogenic lipoprotein phenotype measured with density gradient ultracentrifugation predict changes in carotid intima-media thickness in men and women. | Vascular health and risk management 20120101 |
| Metabolic syndrome in the Mediterranean region: Current status. | Indian journal of endocrinology and metabolism 20120101 |
| Hypertriglyceridemia-induced recurrent acute pancreatitis: A case-based review. | Indian journal of endocrinology and metabolism 20120101 |
| Development and validation of a repharsed phase- HPLC method for simultaneous determination of rosiglitazone and glimepiride in combined dosage forms and human plasma. | Chemistry Central journal 20120101 |
| Relaxation of rat thoracic aorta by fibrate drugs correlates with their potency to disturb intracellular calcium of VSMCs. | Vascular pharmacology 20120101 |
| PPARs in Regulation of Paraoxonases: Control of Oxidative Stress and Inflammation Pathways. | PPAR research 20120101 |
| Niacin extended-release/simvastatin combination therapy produces larger favorable changes in high-density lipoprotein particles than atorvastatin monotherapy. | Vascular health and risk management 20120101 |
| Effect of gemfibrozil on the pharmacokinetics of mitiglinide in rats. | Arzneimittel-Forschung 20120101 |
| 5, 8, 11, 14-eicosatetraynoic acid suppresses CCL2/MCP-1 expression in IFN-γ-stimulated astrocytes by increasing MAPK phosphatase-1 mRNA stability. | Journal of neuroinflammation 20120101 |
| Enhanced solubility and functionality of valrubicin (AD-32) against cancer cells upon encapsulation into biocompatible nanoparticles. | International journal of nanomedicine 20120101 |
| Chemosensitization as a means to augment commercial antifungal agents. | Frontiers in microbiology 20120101 |
| Effects of bezafibrate on lipid and glucose metabolism in dyslipidemic patients with diabetes: the J-BENEFIT study. | Cardiovascular diabetology 20120101 |
| Rosuvastatin: a review of the pharmacology and clinical effectiveness in cardiovascular disease. | Clinical Medicine Insights. Cardiology 20120101 |
| The renoprotective actions of peroxisome proliferator-activated receptors agonists in diabetes. | PPAR research 20120101 |
| Regulation of reverse cholesterol transport - a comprehensive appraisal of available animal studies. | Nutrition & metabolism 20120101 |
| Achieving secondary prevention low-density lipoprotein particle concentration goals using lipoprotein cholesterol-based data. | PloS one 20120101 |
| New insights into the role of peroxisome proliferator-activated receptors in regulating the inflammatory response after tissue injury. | PPAR research 20120101 |
| Genomics of Dementia: APOE- and CYP2D6-Related Pharmacogenetics. | International journal of Alzheimer's disease 20120101 |
| The promoter of Rv0560c is induced by salicylate and structurally-related compounds in Mycobacterium tuberculosis. | PloS one 20120101 |
| Cardiovascular events in patients received combined fibrate/statin treatment versus statin monotherapy: Acute Coronary Syndrome Israeli Surveys data. | PloS one 20120101 |
| A comparative clinical study of hypolipidemic efficacy of Amla (Emblica officinalis) with 3-hydroxy-3-methylglutaryl-coenzyme-A reductase inhibitor simvastatin. | Indian journal of pharmacology 20120101 |
| Fenofibrate enhances the in vitro differentiation of foxp3(+) regulatory T cells in mice. | PPAR research 20120101 |
| Systematic analysis of cell cycle effects of common drugs leads to the discovery of a suppressive interaction between gemfibrozil and fluoxetine. | PloS one 20120101 |
| Failure to Control Caries in an AIDS-Affected Individual: A Case Report. | Case reports in dentistry 20120101 |
| Identification of amino acids essential for estrone-3-sulfate transport within transmembrane domain 2 of organic anion transporting polypeptide 1B1. | PloS one 20120101 |
| Design novel dual agonists for treating type-2 diabetes by targeting peroxisome proliferator-activated receptors with core hopping approach. | PloS one 20120101 |
| All-Trans Retinoic Acid-Induced Pseudotumor Cerebri during Induction Therapy for Acute Promyelocytic Leukemia: A Case Report and Literature Review. | Case reports in oncological medicine 20120101 |
| Removal of pharmaceuticals in biologically treated wastewater by chlorine dioxide or peracetic acid. | Environmental technology 20120101 |
| Leaching of pharmaceuticals and personal care products in turfgrass soils during recycled water irrigation. | Journal of environmental quality 20120101 |
| Immunotoxic potential of aeration lagoon effluents for the treatment of domestic and hospital wastewaters in the freshwater mussel Elliptio complanata. | Journal of environmental sciences (China) 20120101 |
| A neutral risk on the development of new-onset diabetes mellitus (NODM) in Taiwanese patients with dyslipidaemia treated with fibrates. | TheScientificWorldJournal 20120101 |
| Removal of trace organic chemical contaminants by a membrane bioreactor. | Water science and technology : a journal of the International Association on Water Pollution Research 20120101 |
| PPARα-Independent Arterial Smooth Muscle Relaxant Effects of PPARα Agonists. | PPAR research 20120101 |
| Patient with hypertriglyceridemia, type 2 diabetes, and chronic kidney disease treated with atorvastatin and omega-3 Fatty Acid ethyl esters. | The open cardiovascular medicine journal 20120101 |
| IMproving the imPlemEntation of cuRrent guidelines for the mAnagement of major coronary hearT disease rIsk factors by multifactorial interVEntion. The IMPERATIVE renal analysis. | Archives of medical science : AMS 20111231 |
| Reconnaissance of selected PPCP compounds in Costa Rican surface waters. | Water research 20111215 |
| Studies to further investigate the inhibition of human liver microsomal CYP2C8 by the acyl-β-glucuronide of gemfibrozil. | Drug metabolism and disposition: the biological fate of chemicals 20111201 |
| Familial hypercholesterolemia: present and future management. | Current cardiology reports 20111201 |
| The PPAR alpha agonist gemfibrozil is an ineffective treatment for spinal cord injured mice. | Experimental neurology 20111201 |
| Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps). | PLoS computational biology 20111201 |
| High levels of remnant lipoprotein cholesterol is a risk factor for large artery atherosclerotic stroke. | Journal of clinical neurology (Seoul, Korea) 20111201 |
| The effect of bezafibrate and omega-3 fatty acids on lymphocyte cytokine release and systemic inflammation in patients with isolated hypertriglyceridemia. | European journal of clinical pharmacology 20111101 |
| Synthesis of novel N-(2-hydroxy-2-p-tolylethyl)-amide and N-(2-oxo-2-p-tolylethyl)-amide derivatives and their antidyslipidemic and antioxidant activity. | Bioorganic & medicinal chemistry letters 20111101 |
| Validation and use of in vivo solid phase micro-extraction (SPME) for the detection of emerging contaminants in fish. | Chemosphere 20111101 |
| The effects of statin and niacin on plaque stability, plaque regression, inflammation and oxidative stress in patients with mild to moderate coronary artery stenosis. | Korean circulation journal 20111101 |
| Evaluation of enhanced coagulation pretreatment to improve ozone oxidation efficiency in wastewater. | Water research 20111015 |
| Dose-dependent interaction between gemfibrozil and repaglinide in humans: strong inhibition of CYP2C8 with subtherapeutic gemfibrozil doses. | Drug metabolism and disposition: the biological fate of chemicals 20111001 |
| Can pharmaceuticals interfere with the synthesis of active androgens in male fish? An in vitro study. | Marine pollution bulletin 20111001 |
| Temporal variation of pharmaceuticals in an urban and agriculturally influenced stream. | The Science of the total environment 20111001 |
| Gemfibrozil hepatotoxicity: a case report. | International journal of clinical pharmacy 20111001 |
| Discovery of gemfibrozil analogues that activate PPARα and enhance the expression of gene CPT1A involved in fatty acids catabolism. | European journal of medicinal chemistry 20111001 |
| Incidence of hospitalized rhabdomyolysis with statin and fibrate use in an insured US population. | The Annals of pharmacotherapy 20111001 |
| Trace analysis of acidic pharmaceutical residues in waters with isotope dilution gas chromatography-mass spectrometry via methylation derivatization. | Talanta 20110930 |
| Dual role of physical workload and occupational noise in the association of the metabolic syndrome with risk of coronary heart disease: findings from the Helsinki Heart Study. | Occupational and environmental medicine 20110901 |
| Impact of intestinal glucuronidation on the pharmacokinetics of raloxifene. | Drug metabolism and disposition: the biological fate of chemicals 20110901 |
| [Study on the pharmacokinetics of tashinone II(A) -loaded polylactic acid nanoparticles in rabbit]. | Zhong yao cai = Zhongyaocai = Journal of Chinese medicinal materials 20110901 |
| PPARs are a unique set of fatty acid regulated transcription factors controlling both lipid metabolism and inflammation. | Biochimica et biophysica acta 20110801 |
| Fenofibrate: a review of its lipid-modifying effects in dyslipidemia and its vascular effects in type 2 diabetes mellitus. | American journal of cardiovascular drugs : drugs, devices, and other interventions 20110801 |
| Reversal of drug-induced rhabdomyolysis on bone scan. | Clinical nuclear medicine 20110801 |
| Role of Peroxisome Proliferator-Activated Receptor α in Diabetic Nephropathy. | Diabetes & metabolism journal 20110801 |
| Ask the doctor. On my last blood test, my triglycerides were 280. Should I be worried about that? My doctor wants me to start taking something called Lopid. Is there another solution? | Harvard heart letter : from Harvard Medical School 20110801 |
| Fenretinide metabolism in humans and mice: utilizing pharmacological modulation of its metabolic pathway to increase systemic exposure. | British journal of pharmacology 20110701 |
| Effect of statin and fibrate treatment on inflammation in type 2 diabetes. A randomized, cross-over study. | Diabetes research and clinical practice 20110701 |
| Aquivalence revisited--new model formulation and application to assess environmental fate of ionic pharmaceuticals in Hamilton Harbour, Lake Ontario. | Environment international 20110701 |
| Effects of the pharmaceuticals gemfibrozil and diclofenac on biomarker expression in the zebra mussel (Dreissena polymorpha) and their comparison with standardised toxicity tests. | Chemosphere 20110701 |
| Effects of the pharmaceuticals gemfibrozil and diclofenac on the marine mussel (Mytilus spp.) and their comparison with standardized toxicity tests. | Marine pollution bulletin 20110701 |
| Occurrence and suitability of sucralose as an indicator compound of wastewater loading to surface waters in urbanized regions. | Water research 20110701 |
| Monitoring of pharmaceutically active compounds on the Guadalquivir River basin (Spain): occurrence and risk assessment. | Journal of environmental monitoring : JEM 20110701 |
| Synthesis, characterization and in vitro hydrolysis of a gemfibrozil-nicotinic acid codrug for improvement of lipid profile. | European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences 20110614 |
| The influence of gemfibrozil on malondialdehyde level and paraoxonase 1 activity in wistar and fisher rats. | Basic & clinical pharmacology & toxicology 20110601 |
| Clinical importance of OATP1B1 and OATP1B3 in drug-drug interactions. | Drug metabolism and pharmacokinetics 20110601 |
| Prediction of the overall renal tubular secretion and hepatic clearance of anionic drugs and a renal drug-drug interaction involving organic anion transporter 3 in humans by in vitro uptake experiments. | Drug metabolism and disposition: the biological fate of chemicals 20110601 |
| Cytotoxicity assessment of four pharmaceutical compounds on the zebra mussel (Dreissena polymorpha) haemocytes, gill and digestive gland primary cell cultures. | Chemosphere 20110601 |
| Triglyceride-rich lipoproteins and high-density lipoprotein cholesterol in patients at high risk of cardiovascular disease: evidence and guidance for management. | European heart journal 20110601 |
| Fenofibrate: altered renal function. | Prescrire international 20110601 |
| Applicability of sucrose laurate as surfactant in solid dispersions prepared by melt technology. | International journal of pharmaceutics 20110530 |
| Comparison of four extraction methods for the analysis of pharmaceuticals in wastewater. | Journal of chromatography. A 20110506 |
| Human pharmacokinetic prediction of UDP-glucuronosyltransferase substrates with an animal scale-up approach. | Drug metabolism and disposition: the biological fate of chemicals 20110501 |
| Reevaluation of the microsomal metabolism of montelukast: major contribution by CYP2C8 at clinically relevant concentrations. | Drug metabolism and disposition: the biological fate of chemicals 20110501 |
| The effect of gemfibrozil, niacin and cholestyramine combination therapy on metabolic syndrome in the Armed Forces Regression Study. | The American journal of the medical sciences 20110501 |
| Native low-density lipoprotein-dependent interleukin-8 production through pertussis toxin-sensitive G-protein coupled receptors and hydrogen peroxide generation contributes to migration of human aortic smooth muscle cells. | Yonsei medical journal 20110501 |
| Effects of selected pharmaceutically active compounds on treatment performance in sequencing batch reactors mimicking wastewater treatment plants operations. | Water research 20110501 |
| Sweet potato (Ipomoea batatas L.) leaves suppressed oxidation of low density lipoprotein (LDL) in vitro and in human subjects. | Journal of clinical biochemistry and nutrition 20110501 |
| Dehydroepiandrosterone (DHEA) replacement decreases insulin resistance and lowers inflammatory cytokines in aging humans. | Aging 20110501 |
| Seasonal variation in the occurrence and removal of pharmaceuticals and personal care products in different biological wastewater treatment processes. | Environmental science & technology 20110415 |
| Involvement of CYP3A4/5 and CYP2D6 in the metabolism of aconitine using human liver microsomes and recombinant CYP450 enzymes. | Toxicology letters 20110410 |
| Mechanism-based inactivation of CYP2C8 by gemfibrozil occurs rapidly in humans. | Clinical pharmacology and therapeutics 20110401 |
| Occurrence and behavior of non-steroidal anti-inflammatory drugs and lipid regulators in wastewater and urban river water of the Pearl River Delta, South China. | Journal of environmental monitoring : JEM 20110401 |
| The causes and consequences of low levels of high density lipoproteins in patients with diabetes. | Diabetes & metabolism journal 20110401 |
| Use of fibrates in the United States and Canada. | JAMA 20110323 |
| The fibrate drug gemfibrozil disrupts lipoprotein metabolism in rainbow trout. | Toxicology and applied pharmacology 20110315 |
| Pharmaceuticals, hormones and bisphenol A in untreated source and finished drinking water in Ontario, Canada--occurrence and treatment efficiency. | The Science of the total environment 20110315 |
| Effect of gemfibrozil and fenofibrate on the pharmacokinetics of atorvastatin. | Journal of clinical pharmacology 20110301 |
| Rapid reduction of severely elevated serum triglycerides with insulin infusion, gemfibrozil and niacin. | Clinical medicine & research 20110301 |
| Fibrate use in diabetes: new concepts. | Journal of diabetes 20110301 |
| Depressogenic effects of medications: a review. | Dialogues in clinical neuroscience 20110301 |
| Nutritional and metabolic status of HIV-positive patients with lipodystrophy during one year of follow-up. | Clinics (Sao Paulo, Brazil) 20110301 |
| Biphasic regulation of intracellular calcium by gemfibrozil contributes to inhibiting L6 myoblast differentiation: implications for clinical myotoxicity. | Chemical research in toxicology 20110218 |
| Two-step stacking in capillary zone electrophoresis featuring sweeping and micelle to solvent stacking: II. Organic anions. | Journal of chromatography. A 20110218 |
| Attenuation of contaminants of emerging concern during surface-spreading aquifer recharge. | The Science of the total environment 20110215 |
| The CYP2C8 inhibitor gemfibrozil does not affect the pharmacokinetics of zafirlukast. | European journal of clinical pharmacology 20110201 |
| Statin therapy in metabolic syndrome and hypertension post-JUPITER: what is the value of CRP? | Current atherosclerosis reports 20110201 |
| Effluent-dominated streams. Part 2: Presence and possible effects of pharmaceuticals and personal care products in Wascana Creek, Saskatchewan, Canada. | Environmental toxicology and chemistry 20110201 |
| Analysis of the presence of cardiovascular and analgesic/anti-inflammatory/antipyretic pharmaceuticals in river- and drinking-water of the Madrid Region in Spain. | Chemosphere 20110201 |
| Differential effects of gemfibrozil and fenofibrate on reverse cholesterol transport from macrophages to feces in vivo. | Biochimica et biophysica acta 20110201 |
| Impact of obesity on hypertension-induced cardiac remodeling: role of oxidative stress and its modulation by gemfibrozil treatment in rats. | Free radical biology & medicine 20110115 |
| The subtypes of peroxisome proliferator-activated receptors expressed by human podocytes and their role in decreasing podocyte injury. | British journal of pharmacology 20110101 |
| Toxicological evaluation of acyl glucuronides of nonsteroidal anti-inflammatory drugs using human embryonic kidney 293 cells stably expressing human UDP-glucuronosyltransferase and human hepatocytes. | Drug metabolism and disposition: the biological fate of chemicals 20110101 |
| Cleanup strategies and advantages in the determination of several therapeutic classes of pharmaceuticals in wastewater samples by SPE-LC-MS/MS. | Analytical and bioanalytical chemistry 20110101 |
| Effects of selected pharmaceutically active compounds on the ammonia oxidizing bacterium Nitrosomonas europaea. | Chemosphere 20110101 |
| Identification of reaction products from reactions of free chlorine with the lipid-regulator gemfibrozil. | Water research 20110101 |
| Standards of medical care in diabetes--2011. | Diabetes care 20110101 |
| Transforming Growth Factor-β1 as a Common Target Molecule for Development of Cardiovascular Diseases, Renal Insufficiency and Metabolic Syndrome. | Cardiology research and practice 20110101 |
| Atherosclerosis and thrombosis: insights from large animal models. | Journal of biomedicine & biotechnology 20110101 |
| Comparative effectiveness of guidelines for the management of hyperlipidemia and hypertension for type 2 diabetes patients. | PloS one 20110101 |
| Megalin/LRP2 expression is induced by peroxisome proliferator-activated receptor -alpha and -gamma: implications for PPARs' roles in renal function. | PloS one 20110101 |
| Effects of currently prescribed LDL-C-lowering drugs on PCSK9 and implications for the next generation of LDL-C-lowering agents. | Lipids in health and disease 20110101 |
| A Canadian Critical Care Trials Group project in collaboration with the international forum for acute care trialists - Collaborative H1N1 Adjuvant Treatment pilot trial (CHAT): study protocol and design of a randomized controlled trial. | Trials 20110101 |
| Induction of P450 3A1/2 and 2C6 by gemfibrozil in Sprague-Dawley rats. | Pharmacological reports : PR 20110101 |
| Apolipoprotein E epsilon-4 polymorphism is associated with younger age at referral to a lipidology clinic and a poorer response to lipid-lowering therapy. | Lipids in health and disease 20110101 |
| Effects of short-term treatment with atorvastatin in smokers with asthma--a randomized controlled trial. | BMC pulmonary medicine 20110101 |
| Drug induced psoriasis. | Acta dermatovenerologica Croatica : ADC 20110101 |
| The role of high-density lipoproteins in reducing the risk of vascular diseases, neurogenerative disorders, and cancer. | Cholesterol 20110101 |
| Characteristics of high-density lipoprotein subclasses distribution for subjects with desirable total cholesterol levels. | Lipids in health and disease 20110101 |
| [Amorphous form in pharmaceutical technological research]. | Acta pharmaceutica Hungarica 20110101 |
| Platinum agent-induced hypersensitivity reactions: data mining of the public version of the FDA adverse event reporting system, AERS. | International journal of medical sciences 20110101 |
| Dyslipidemia associated with chronic kidney disease. | The open cardiovascular medicine journal 20110101 |
| HIV and HAART-Associated Dyslipidemia. | The open cardiovascular medicine journal 20110101 |
| Prosthetic aortic valve stenosis in end-stage renal failure. | International journal of nephrology 20110101 |
| An international randomised placebo-controlled trial of a four-component combination pill ('polypill') in people with raised cardiovascular risk. | PloS one 20110101 |
| Dyslipidaemia of obesity, metabolic syndrome and type 2 diabetes mellitus: the case for residual risk reduction after statin treatment. | The open cardiovascular medicine journal 20110101 |
| Generation of polyclonal antibody with high avidity to rosuvastatin and its use in development of highly sensitive ELISA for determination of rosuvastatin in plasma. | Chemistry Central journal 20110101 |
| Effect of atorvastatin therapy on oxidant-antioxidant status and atherosclerotic plaque formation. | Vascular health and risk management 20110101 |
| Possible involvement of caveolin in attenuation of cardioprotective effect of ischemic preconditioning in diabetic rat heart. | BMC cardiovascular disorders 20110101 |
| Targeting Nuclear Hormone Receptors: PPARα Agonists as Potential Disease-Modifying Drugs for Rheumatoid Arthritis. | International journal of rheumatology 20110101 |
| Treating statin-intolerant patients. | Diabetes, metabolic syndrome and obesity : targets and therapy 20110101 |
| Primary prevention of coronary heart disease: integration of new data, evolving views, revised goals, and role of rosuvastatin in management. A comprehensive survey. | Drug design, development and therapy 20110101 |
| Paraoxonase (PON1 and PON3) Polymorphisms: Impact on Liver Expression and Atorvastatin-Lactone Hydrolysis. | Frontiers in pharmacology 20110101 |
| Stepwise approach to myopathy in systemic disease. | Frontiers in neurology 20110101 |
| Spinal cord injury: From inflammation to glial scar. | Surgical neurology international 20110101 |
| The role of common variants of the cholesteryl ester transfer protein gene in left main coronary artery disease. | Lipids in health and disease 20110101 |
| Sinomenine inhibits microglial activation by Aβ and confers neuroprotection. | Journal of neuroinflammation 20110101 |
| RLIP76, a glutathione-conjugate transporter, plays a major role in the pathogenesis of metabolic syndrome. | PloS one 20110101 |
| Antioxidant and inflammatory aspects of lipoprotein-associated phospholipase A₂ (Lp-PLA₂): a review. | Lipids in health and disease 20110101 |
| Rhabdomyolysis associated with fenofibrate monotherapy in a patient with chronic myelogenous leukemia. | Case reports in gastroenterology 20110101 |
| Medicinal Chemistry and Actions of Dual and Pan PPAR Modulators. | The open medicinal chemistry journal 20110101 |
| Prevalence, Predictors, and Impact of Low High-Density Lipoprotein Cholesterol on in-Hospital Outcomes Among Acute Coronary Syndrome Patients in the Middle East. | The open cardiovascular medicine journal 20110101 |
| Long-term fenofibrate treatment impaired glucose-stimulated insulin secretion and up-regulated pancreatic NF-kappa B and iNOS expression in monosodium glutamate-induced obese rats: is that a latent disadvantage? | Journal of translational medicine 20110101 |
| Multimodal cardiovascular magnetic resonance quantifies regional variation in vascular structure and function in patients with coronary artery disease: relationships with coronary disease severity. | Journal of cardiovascular magnetic resonance : official journal of the Society for Cardiovascular Magnetic Resonance 20110101 |
| Low incidence of paradoxical reductions in HDL-C levels in dyslipidemic patients treated with fenofibrate alone or in combination with ezetimibe or ezetimibe/simvastatin. | Lipids in health and disease 20110101 |
| 13-hydroxy linoleic acid increases expression of the cholesterol transporters ABCA1, ABCG1 and SR-BI and stimulates apoA-I-dependent cholesterol efflux in RAW264.7 macrophages. | Lipids in health and disease 20110101 |
| Characterization of Abcc4 gene amplification in stepwise-selected mouse J774 macrophages resistant to the topoisomerase II inhibitor ciprofloxacin. | PloS one 20110101 |
| Rosiglitazone and fenofibrate additive effects on lipids. | Cholesterol 20110101 |
| Calciphylaxis presenting in early chronic kidney disease with mixed hyperparathyroidism. | International journal of nephrology and renovascular disease 20110101 |
| Association of PPARα Intron 7 Polymorphism with Coronary Artery Disease: A Cross-Sectional Study. | ISRN cardiology 20110101 |
| No consensus on definition criteria for stroke registry common data elements. | Cerebrovascular diseases extra 20110101 |
| Statins: past and present. | Heart views : the official journal of the Gulf Heart Association 20110101 |
| Using Complementary and Alternative Medicines to Target the Host Response during Severe Influenza. | Evidence-based complementary and alternative medicine : eCAM 20101201 |
| Impact of increases in high-density lipoprotein cholesterol on cardiovascular outcomes during the armed forces regression study. | Journal of cardiovascular pharmacology and therapeutics 20101201 |
| Occurrence and loss over three years of 72 pharmaceuticals and personal care products from biosolids-soil mixtures in outdoor mesocosms. | Water research 20101201 |
| CXCL9 and CXCL11 chemokines modulation by peroxisome proliferator-activated receptor-alpha agonists secretion in Graves' and normal thyrocytes. | The Journal of clinical endocrinology and metabolism 20101201 |
| A predictive ligand-based Bayesian model for human drug-induced liver injury. | Drug metabolism and disposition: the biological fate of chemicals 20101201 |
| Common genetic variation in multiple metabolic pathways influences susceptibility to low HDL-cholesterol and coronary heart disease. | Journal of lipid research 20101201 |
| Statins alter intracellular calcium homeostasis in malignant hyperthermia susceptible individuals. | Cardiovascular therapeutics 20101201 |
| Validation of an LC/MS method for the determination of gemfibrozil in human plasma and its application to a pharmacokinetic study. | Biomedical chromatography : BMC 20101201 |
| Repaglinide-gemfibrozil drug interaction: inhibition of repaglinide glucuronidation as a potential additional contributing mechanism. | British journal of clinical pharmacology 20101201 |
| Successful drug development despite adverse preclinical findings part 2: examples. | Journal of toxicologic pathology 20101201 |
| Occurrence, temporal evolution and risk assessment of pharmaceutically active compounds in Doñana Park (Spain). | Journal of hazardous materials 20101115 |
| Chronic treatment with fibrates elevates superoxide dismutase in adult mouse brain microvessels. | Brain research 20101104 |
| Synthesis and SAR studies of 1,4-benzoxazine MenB inhibitors: novel antibacterial agents against Mycobacterium tuberculosis. | Bioorganic & medicinal chemistry letters 20101101 |
| Comparative physical, mechanical and crystallographic properties of a series of gemfibrozil salts. | The Journal of pharmacy and pharmacology 20101101 |
| Human health risk assessment of pharmaceuticals in water: issues and challenges ahead. | International journal of environmental research and public health 20101101 |
| Diabetes & coronary heart disease: current perspectives. | The Indian journal of medical research 20101101 |
| Two different spectrofluorimetric methods for simultaneous determination of gemfibrozil and rosiglitazone in human plasma. | Talanta 20101015 |
| Atherogenic dyslipidemia: cardiovascular risk and dietary intervention. | Lipids 20101001 |
| Cerivastatin in vitro metabolism by CYP2C8 variants found in patients experiencing rhabdomyolysis. | Pharmacogenetics and genomics 20101001 |
| [Facial edema due to gemfibrozil]. | Medicina clinica 20100911 |
| Lipid Lowering Activity of Anthocephalus indicus Root in Hyperlipidemic Rats. | Evidence-based complementary and alternative medicine : eCAM 20100901 |
| Effect of a single gemfibrozil dose on the pharmacokinetics of rosuvastatin in bile and plasma in healthy volunteers. | Journal of clinical pharmacology 20100901 |
| Application of a novel solid-phase-extraction sampler and ultra-performance liquid chromatography quadrupole-time-of-flight mass spectrometry for determination of pharmaceutical residues in surface sea water. | Chemosphere 20100901 |
| Results of a safety initiative for patients on concomitant amiodarone and simvastatin therapy in a Veterans Affairs medical center. | Journal of managed care pharmacy : JMCP 20100901 |
| Evolution of absorbance spectra of ozonated wastewater and its relationship with the degradation of trace-level organic species. | Environmental science & technology 20100815 |
| Management of hypertriglyceridemia in the diabetic patient. | Current diabetes reports 20100801 |
| Gemfibrozil markedly increases the plasma concentrations of montelukast: a previously unrecognized role for CYP2C8 in the metabolism of montelukast. | Clinical pharmacology and therapeutics 20100801 |
| Antihyperlipidemic activity of Clitoria ternatea and Vigna mungo in rats. | Pharmaceutical biology 20100801 |
| Occurrence and risk assessment of acidic pharmaceuticals in the Yellow River, Hai River and Liao River of north China. | The Science of the total environment 20100715 |
| Novel coumarin derivatives as potential antidyslipidemic agents. | Bioorganic & medicinal chemistry letters 20100715 |
| Role of Esrrg in the fibrate-mediated regulation of lipid metabolism genes in human ApoA-I transgenic mice. | The pharmacogenomics journal 20100601 |
| Design and synthesis of 2,4-disubstituted polyhydroquinolines as prospective antihyperglycemic and lipid modulating agents. | Bioorganic & medicinal chemistry 20100601 |
| Multi-residue method for the analysis of pharmaceutical compounds in sewage sludge, compost and sediments by sonication-assisted extraction and LC determination. | Journal of separation science 20100601 |
| Systematic review on evidence of the effectiveness of cholesterol-lowering drugs. | Advances in therapy 20100601 |
| Occurrence and a screening-level risk assessment of human pharmaceuticals in the Pearl River system, South China. | Environmental toxicology and chemistry 20100601 |
| Presence of pharmaceutically active compounds in Doñana Park (Spain) main watersheds. | Journal of hazardous materials 20100515 |
| Synthesis of novel benzocoumarin derivatives as lipid lowering agents. | Bioorganic & medicinal chemistry letters 20100515 |
| Occurrence and fate of pharmaceuticals in wastewater treatment plants and rivers in Korea. | Environmental pollution (Barking, Essex : 1987) 20100501 |
| Suppressive effect of insulin infusion on chemokines and chemokine receptors. | Diabetes care 20100501 |
| The nasty surprise of a complex drug-drug interaction. | Drug discovery today 20100501 |
| Tissue-specific in vivo bioconcentration of pharmaceuticals in rainbow trout (Oncorhynchus mykiss) using space-resolved solid-phase microextraction. | Environmental science & technology 20100501 |
| Potential chemical and microbiological risks on human health from urban wastewater reuse in agriculture. Case study of wastewater effluents in Spain. | Journal of environmental science and health. Part. B, Pesticides, food contaminants, and agricultural wastes 20100501 |
| Clinical management of pandemic 2009 influenza A(H1N1) infection. | Chest 20100401 |
| Effects of statins vs. non-statin lipid-lowering therapy on bone formation and bone mineral density biomarkers in patients with hyperlipidemia. | Bone 20100401 |
| [Problems with statins and the marketing of these medications]. | Revista medica de Chile 20100401 |
| Expression of prestin and Gata-3,-2,-1 mRNA in the rat organ of Corti during the postnatal period and in culture. | Hearing research 20100301 |
| Effect of auxiliary substances on complexation efficiency and intrinsic dissolution rate of gemfibrozil-beta-CD complexes. | AAPS PharmSciTech 20100301 |
| Management of dyslipidemia in people with type 2 diabetes mellitus. | Reviews in endocrine & metabolic disorders 20100301 |
| Study on the matrix effect in the determination of selected pharmaceutical residues in seawater by solid-phase extraction and ultra-high-performance liquid chromatography-electrospray ionization low-energy collision-induced dissociation tandem mass spectrometry. | Journal of chromatography. A 20100226 |
| Myelin basic protein priming reduces the expression of Foxp3 in T cells via nitric oxide. | Journal of immunology (Baltimore, Md. : 1950) 20100215 |
| Combined therapy in the treatment of dyslipidemia. | Fundamental & clinical pharmacology 20100201 |
| Synthesis and biological evaluation of N-aryl-1,4-dihydropyridines as novel antidyslipidemic and antioxidant agents. | European journal of medicinal chemistry 20100201 |
| Safety and tolerability of dalcetrapib (RO4607381/JTT-705): results from a 48-week trial. | European heart journal 20100201 |
| Fibrate/Statin initiation in warfarin users and gastrointestinal bleeding risk. | The American journal of medicine 20100201 |
| Simultaneous determination of acidic, neutral and basic pharmaceuticals in urban wastewater by ultra high-pressure liquid chromatography-tandem mass spectrometry. | Journal of chromatography. A 20100129 |
| Lipid metabolism and hyperlipidemia in dogs. | Veterinary journal (London, England : 1997) 20100101 |
| Ecotoxicity assessment of lipid regulators in water and biologically treated wastewater using three aquatic organisms. | Environmental science and pollution research international 20100101 |
| Role of PPARs in Radiation-Induced Brain Injury. | PPAR research 20100101 |
| Cholesteryl ester transfer protein: at the heart of the action of lipid-modulating therapy with statins, fibrates, niacin, and cholesteryl ester transfer protein inhibitors. | European heart journal 20100101 |
| HIV-associated dyslipidaemia among HIV antibody-positive patients in Ireland: prevalence and management strategies. | International journal of STD & AIDS 20100101 |
| Validation of cell-based OATP1B1 assays to assess drug transport and the potential for drug-drug interaction to support regulatory submissions. | Xenobiotica; the fate of foreign compounds in biological systems 20100101 |
| Gemfibrozil-induced myositis in a patient with normal renal function. | The Annals of pharmacotherapy 20100101 |
| A synergism model for PPARalpha and PXR agonist effects on HDL-cholesterol and apoA1. | Frontiers in bioscience (Elite edition) 20100101 |
| Standards of medical care in diabetes--2010. | Diabetes care 20100101 |
| Erythema multiforme associated with gemfibrozil monotherapy. | The American journal of the medical sciences 20100101 |
| Implications of human pharmaceutical occurrence in the Sindian river of Taiwan: a strategic study of risk assessment. | Journal of environmental monitoring : JEM 20100101 |
| Rosuvastatin-associated adverse effects and drug-drug interactions in the clinical setting of dyslipidemia. | American journal of cardiovascular drugs : drugs, devices, and other interventions 20100101 |
| Peroxisome proliferator-activated receptor (PPAR): balance for survival in parasitic infections. | Journal of biomedicine & biotechnology 20100101 |
| System-dependent outcomes during the evaluation of drug candidates as inhibitors of cytochrome P450 (CYP) and uridine diphosphate glucuronosyltransferase (UGT) enzymes: human hepatocytes versus liver microsomes versus recombinant enzymes. | Drug metabolism and pharmacokinetics 20100101 |
| EVITA: a tool for the early evaluation of pharmaceutical innovations with regard to therapeutic advantage. | BMC clinical pharmacology 20100101 |
| Current status and future directions in lipid management: emphasizing low-density lipoproteins, high-density lipoproteins, and triglycerides as targets for therapy. | Vascular health and risk management 20100101 |
| Time-dependent integrity during storage of natural surface water samples for the trace analysis of pharmaceutical products, feminizing hormones and pesticides. | Chemistry Central journal 20100101 |
| PPARalpha: energy combustion, hypolipidemia, inflammation and cancer. | Nuclear receptor signaling 20100101 |
| Critical appraisal of laropiprant and extended-release niacin combination in the management of mixed dyslipidemias and primary hypercholesterolemia. | Therapeutics and clinical risk management 20100101 |
| Nutrigenomics therapy of hepatisis C virus induced-hepatosteatosis. | BMC gastroenterology 20100101 |
| Fenofibric acid: a new fibrate approved for use in combination with statin for the treatment of mixed dyslipidemia. | Vascular health and risk management 20100101 |
| Prevention of cardiovascular disease utilizing fibrates--a pooled meta-analysis. | American journal of therapeutics 20100101 |
| Paraoxonase: Its antiatherogenic role in chronic renal failure. | Indian journal of nephrology 20100101 |
| Effects of high sucrose diet, gemfibrozil, and their combination on plasma paraoxonase 1 activity and lipid levels in rats. | Acta biochimica Polonica 20100101 |
| 'If it ain't broke, don't fix it': a commentary on the positive-negative results of the ACCORD Lipid study. | Cardiovascular diabetology 20100101 |
| The efficacy and safety of insulin-sensitizing drugs in HIV-associated lipodystrophy syndrome: a meta-analysis of randomized trials. | BMC infectious diseases 20100101 |
| Gene activation regresses atherosclerosis, promotes health, and enhances longevity. | Lipids in health and disease 20100101 |
| Use of statin therapy to reduce cardiovascular risk in older patients. | Current gerontology and geriatrics research 20100101 |
| Evidence of direct smooth muscle relaxant effects of the fibrate gemfibrozil. | Journal of smooth muscle research = Nihon Heikatsukin Gakkai kikanshi 20100101 |
| Management of dyslipidemias with fibrates, alone and in combination with statins: role of delayed-release fenofibric acid. | Vascular health and risk management 20100101 |
| Lack of association between peroxisome proliferator-activated receptors alpha and gamma2 polymorphisms and progressive liver damage in patients with non-alcoholic fatty liver disease: a case control study. | BMC gastroenterology 20100101 |
| The Role of PPARα Activation in Liver and Muscle. | PPAR research 20100101 |
| Atherogenic dyslipidemia and diabetes mellitus: what's new in the management arena? | Vascular health and risk management 20100101 |
| PPARα in Obesity: Sex Difference and Estrogen Involvement. | PPAR research 20100101 |
| Methods of chromatographic determination of medicines decreasing the level of cholesterol. | Acta poloniae pharmaceutica 20100101 |
| Peroxisome proliferator-activated receptor alpha target genes. | PPAR research 20100101 |
| The bile acid sensor FXR protects against dyslipidemia and aortic plaques development induced by the HIV protease inhibitor ritonavir in mice. | PloS one 20100101 |
| Effects of the PPARα Agonist and Widely Used Antihyperlipidemic Drug Gemfibrozil on Hepatic Toxicity and Lipid Metabolism. | PPAR research 20100101 |
| Drug interaction and pharmacist. | Journal of young pharmacists : JYP 20100101 |
| Diabetic cardiomyopathy: from the pathophysiology of the cardiac myocytes to current diagnosis and management strategies. | Vascular health and risk management 20100101 |
| RhoA regulates peroxisome association to microtubules and the actin cytoskeleton. | PloS one 20100101 |
| Niacin or ezetimibe for patients with, or at risk of coronary heart disease. | Clinical Medicine Insights. Cardiology 20100101 |
| Lipid control and use of lipid-regulating drugs for prevention of cardiovascular events in Chinese type 2 diabetic patients: a prospective cohort study. | Cardiovascular diabetology 20100101 |
| Clinical evaluation of Dyslipidemia among type II diabetic patients at Public hospital Penang, Malaysia. | International archives of medicine 20100101 |
| Prevalence of lipid abnormalities before and after introduction of lipid modifying therapy among Swedish patients with dyslipidemia (PRIMULA). | BMC public health 20100101 |
| Low high-density lipoprotein cholesterol: current status and future strategies for management. | Vascular health and risk management 20100101 |
| Atorvastatin reduces proteinuria in non-diabetic chronic kidney disease patients partly via lowering serum levels of advanced glycation end products (AGEs). | Oxidative medicine and cellular longevity 20100101 |
| Treatment of dyslipidemia in patients with type 2 diabetes. | Lipids in health and disease 20100101 |
| High density lipoproteins-based therapies for cardiovascular disease. | Journal of cardiovascular disease research 20100101 |
| Combination of niacin extended-release and simvastatin results in a less atherogenic lipid profile than atorvastatin monotherapy. | Vascular health and risk management 20100101 |
| Uses and benefits of omega-3 ethyl esters in patients with cardiovascular disease. | Journal of multidisciplinary healthcare 20100101 |
| Two siblings with familial chylomicronemia syndrome: disease course and effectiveness of early treatment. | Case reports in medicine 20100101 |
| Regulation of Immune Responses and Autoimmune Encephalomyelitis by PPARs. | PPAR research 20100101 |
| Fenofibrate treatment enhances antioxidant status and attenuates endothelial dysfunction in streptozotocin-induced diabetic rats. | Experimental diabetes research 20100101 |
| Drug-drug Interaction between Pravastatin and Gemfibrozil (Antihyperlipidemic) with Gliclazide (Antidiabetic) in Rats. | Journal of young pharmacists : JYP 20100101 |
| Rosuvastatin, inflammation, C-reactive protein, JUPITER, and primary prevention of cardiovascular disease--a perspective. | Drug design, development and therapy 20100101 |
| Glycoxidative stress and cardiovascular complications in experimentally-induced diabetes: effects of antioxidant treatment. | The open cardiovascular medicine journal 20100101 |
| Repaglinide/metformin fixed-dose combination to improve glycemic control in patients with type 2 diabetes: an update. | Diabetes, metabolic syndrome and obesity : targets and therapy 20100101 |
| Pitavastatin: evidence for its place in treatment of hypercholesterolemia. | Core evidence 20100101 |
| Lipid Metabolism and Cardiovascular Risk in HIV-1 Infection and HAART: Present and Future Problems. | Cholesterol 20100101 |
| Randomized Trial of a Pharmacist-Delivered Intervention for Improving Lipid-Lowering Medication Adherence among Patients with Coronary Heart Disease. | Cholesterol 20100101 |
| A study of standardized extracts of Picrorhiza kurroa Royle ex Benth in experimental nonalcoholic fatty liver disease. | Journal of Ayurveda and integrative medicine 20100101 |
| Safety and efficacy of laropiprant and extended-release niacin combination in the management of mixed dyslipidemias and primary hypercholesterolemia. | Drug, healthcare and patient safety 20100101 |
| Drug interaction as cause of spontaneously resolving epidural spinal hematoma on warfarin therapy. | Journal of neurosciences in rural practice 20100101 |
| PPARs and xenobiotic-induced adverse effects: relevance to human health. | PPAR research 20100101 |
| Glucose sensing neurons in the ventromedial hypothalamus. | Sensors (Basel, Switzerland) 20100101 |
| New and emerging agents in the management of lipodystrophy in HIV-infected patients. | HIV/AIDS (Auckland, N.Z.) 20100101 |
| A review on the rationale and clinical use of concomitant rosuvastatin and fenofibrate/fenofibric acid therapy. | Clinical pharmacology : advances and applications 20100101 |
| Occurrence of pharmaceuticals and personal care products in fish: results of a national pilot study in the United States. | Environmental toxicology and chemistry 20091201 |
| Computer-based screening of veterans for metabolic syndrome. | Metabolic syndrome and related disorders 20091201 |
| Rhabdomyolysis associated with fibrate therapy: review of 76 published cases and a new case report. | European journal of clinical pharmacology 20091201 |
| CYP2C8 activity recovers within 96 hours after gemfibrozil dosing: estimation of CYP2C8 half-life using repaglinide as an in vivo probe. | Drug metabolism and disposition: the biological fate of chemicals 20091201 |
| Enterohepatic disposition of rosuvastatin in pigs and the impact of concomitant dosing with cyclosporine and gemfibrozil. | Drug metabolism and disposition: the biological fate of chemicals 20091201 |
| Gemfibrozil in late preterm and term neonates with moderate jaundice: a randomized controlled trial. | Indian pediatrics 20091201 |
| Pyranocoumarins: a new class of anti-hyperglycemic and anti-dyslipidemic agents. | Bioorganic & medicinal chemistry letters 20091115 |
| Phenoxy herbicides and fibrates potently inhibit the human chemosensory receptor subunit T1R3. | Journal of medicinal chemistry 20091112 |
| Novel LMF1 nonsense mutation in a patient with severe hypertriglyceridemia. | The Journal of clinical endocrinology and metabolism 20091101 |
| Triglycerides and HDL cholesterol: stars or second leads in diabetes? | Diabetes care 20091101 |
| Impact of chronic anticholesterol therapy on development of microvascular rarefaction in the metabolic syndrome. | Microcirculation (New York, N.Y. : 1994) 20091101 |
| A reexamination of the PPAR-alpha activation mode of action as a basis for assessing human cancer risks of environmental contaminants. | Environmental health perspectives 20091101 |
| Design, synthesis and hypolipidemic activity of novel 2-(naphthalen-2-yloxy)propionic acid derivatives as desmethyl fibrate analogs. | European journal of medicinal chemistry 20091001 |
| Construction of triple-transfected cells [organic anion-transporting polypeptide (OATP) 1B1/multidrug resistance-associated protein (MRP) 2/MRP3 and OATP1B1/MRP2/MRP4] for analysis of the sinusoidal function of MRP3 and MRP4. | Drug metabolism and disposition: the biological fate of chemicals 20091001 |
| Gemfibrozil concentrations are significantly decreased in the presence of lopinavir-ritonavir. | Journal of acquired immune deficiency syndromes (1999) 20091001 |
| Effect of fibrates on lipid profiles and cardiovascular outcomes: a systematic review. | The American journal of medicine 20091001 |
| [Place of fibrates for the treatment of patients with atherogenic dyslipidemia]. | Revue medicale de Liege 20091001 |
| Probing the fibrate binding specificity of rat liver fatty acid binding protein. | Journal of medicinal chemistry 20090910 |
| AMP-activated protein kinase and nitric oxide regulate the glucose sensitivity of ventromedial hypothalamic glucose-inhibited neurons. | American journal of physiology. Cell physiology 20090901 |
| The mechanism and mitigation of niacin-induced flushing. | International journal of clinical practice 20090901 |
| Positive relationship between dietary fat, ethanol intake, triglycerides, and hypothalamic peptides: counteraction by lipid-lowering drugs. | Alcohol (Fayetteville, N.Y.) 20090901 |
| On the mechanism for PPAR agonists to enhance ABCA1 gene expression. | Atherosclerosis 20090801 |
| Pleiotropic action of short-term metformin and fenofibrate treatment, combined with lifestyle intervention, in type 2 diabetic patients with mixed dyslipidemia. | Diabetes care 20090801 |
| Runoff of pharmaceuticals and personal care products following application of dewatered municipal biosolids to an agricultural field. | The Science of the total environment 20090801 |
| Apolipoprotein B but not LDL cholesterol is associated with coronary artery calcification in type 2 diabetic whites. | Diabetes 20090801 |
| Automated zone-sampling dilution by coupling sequential injection analysis to high-throughput HPLC for the direct determination of gemfibrozil. | Journal of separation science 20090801 |
| Recovery time in a case of gemfibrozil and simvastatin-associated rhabdomyolysis. | Southern medical journal 20090801 |
| Occurrence and removal of pharmaceutically active compounds in sewage treatment plants with different technologies. | Journal of environmental monitoring : JEM 20090801 |
| Effects of gemfibrozil on outcome after permanent middle cerebral artery occlusion in mice. | Brain research 20090707 |
| Estrogenic activity of pharmaceuticals in the aquatic environment. | Environment international 20090701 |
| High-performance liquid chromatography method for determination of carnosic acid in rat plasma and its application to pharmacokinetic study. | Biomedical chromatography : BMC 20090701 |
| Clomiphene citrate-induced severe hypertriglyceridemia. | Fertility and sterility 20090701 |
| Pharmaceutical and personal care products in tile drainage following surface spreading and injection of dewatered municipal biosolids to an agricultural field. | The Science of the total environment 20090701 |
| Benzylic oxidation of gemfibrozil-1-O-beta-glucuronide by P450 2C8 leads to heme alkylation and irreversible inhibition. | Chemical research in toxicology 20090701 |
| A randomized placebo-controlled study on the effect of nifedipine on coronary endothelial function and plaque formation in patients with coronary artery disease: the ENCORE II study. | European heart journal 20090701 |
| Effects of WY-14643 on peroxisomal enzyme activity and hormone secretion in immortalized human trophoblast cells. | Biological & pharmaceutical bulletin 20090701 |
| Elevated creatine phosphokinase levels associated with linezolid therapy. | American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists 20090615 |
| Design, synthesis and hypolipidemic activity of novel 2-(m-tolyloxy) isobutyric acid derivatives. | European journal of medicinal chemistry 20090601 |
| Effects of rosuvastatin and atorvastatin on LDL and HDL particle concentrations in patients with metabolic syndrome: a randomized, double-blind, controlled study. | Diabetes care 20090601 |
| Identification of the efflux transporter of the fluoroquinolone antibiotic ciprofloxacin in murine macrophages: studies with ciprofloxacin-resistant cells. | Antimicrobial agents and chemotherapy 20090601 |
| Occurrence of pharmaceuticals in Taiwan's surface waters: impact of waste streams from hospitals and pharmaceutical production facilities. | The Science of the total environment 20090601 |
| Rapid oxidation of ring methyl groups is the primary mechanism of biotransformation of gemfibrozil by the fungus Cunninghamella elegans. | Archives of microbiology 20090601 |
| Interaction between gemfibrozil and warfarin: case report and review of the literature. | Pharmacotherapy 20090601 |
| Inhibition by fibrates of plasminogen activator inhibitor type-1 expression in human adipocytes and preadipocytes. | Thrombosis and haemostasis 20090601 |
| Hypertriglyceridaemia-induced acute pancreatitis due to patient non-compliance. | Journal of clinical pharmacy and therapeutics 20090601 |
| Omega-3 ethylester concentrate: a review of its use in secondary prevention post-myocardial infarction and the treatment of hypertriglyceridaemia. | Drugs 20090529 |
| Human health risk assessment for peroxisome proliferators: more than 30 years of research. | Experimental and toxicologic pathology : official journal of the Gesellschaft fur Toxikologische Pathologie 20090501 |
| Efficacy of gemfibrozil in the primary prevention of atrial fibrillation in a large randomized controlled trial. | American heart journal 20090501 |
| Managing toxicities and optimal dosing of targeted drugs in advanced kidney cancer. | Current oncology (Toronto, Ont.) 20090501 |
| Antidyslipidemic and antioxidative activities of 8-hydroxyquinoline derived novel keto-enamine Schiffs bases. | European journal of medicinal chemistry 20090401 |
| Antidiabetic action of bezafibrate in a large observational database. | Diabetes care 20090401 |
| Transcriptional modulation of the immune response by peroxisome proliferator-activated receptor-{alpha} agonists in autoimmune disease. | Journal of immunology (Baltimore, Md. : 1950) 20090401 |
| Gene expression profiling in rat liver treated with compounds inducing elevation of bilirubin. | Human & experimental toxicology 20090401 |
| Flushing and other dermatologic adverse events associated with extended-release niacin therapy. | Journal of clinical lipidology 20090401 |
| Hypertriglyceridemia and its pharmacologic treatment among US adults. | Archives of internal medicine 20090323 |
| Myotoxicity of gemfibrozil in cynomolgus monkey model and its relationship to pharmacokinetic properties. | Toxicology and applied pharmacology 20090315 |
| Summaries for patients. Response to cholesterol-lowering drugs in patients with and without HIV infection. | Annals of internal medicine 20090303 |
| Response to newly prescribed lipid-lowering therapy in patients with and without HIV infection. | Annals of internal medicine 20090303 |
| Determination of pharmaceuticals in sewage sludge by pressurized liquid extraction (PLE) coupled to liquid chromatography-tandem mass spectrometry (LC-MS/MS). | Analytical and bioanalytical chemistry 20090301 |
| A high performance liquid chromatography method for simultaneous determination of rosiglitazone and gemfibrozil in human plasma. | Journal of chromatography. B, Analytical technologies in the biomedical and life sciences 20090301 |
| Meeting the challenge of influenza pandemic preparedness in developing countries. | Emerging infectious diseases 20090301 |
| Cholesterol-dependent anaplasma phagocytophilum exploits the low-density lipoprotein uptake pathway. | PLoS pathogens 20090301 |
| Lipid lowering activity of ethanolic extract of leaves of Aegle marmelos (Linn.) in hyperlipidaemic models of Wistar albino rats. | Indian journal of experimental biology 20090301 |
| Free-radical-induced oxidative and reductive degradation of fibrate pharmaceuticals: kinetic studies and degradation mechanisms. | The journal of physical chemistry. A 20090219 |
| Combination statin-fibrate therapy: safety aspects. | Diabetes, obesity & metabolism 20090201 |
| Effects of high-dose simvastatin therapy on glucose metabolism and ectopic lipid deposition in nonobese type 2 diabetic patients. | Diabetes care 20090201 |
| The influence of natural organic matter and cations on the rejection of endocrine disrupting and pharmaceutically active compounds by nanofiltration. | Water research 20090201 |
| Fate and distribution of pharmaceuticals in wastewater and sewage sludge of the conventional activated sludge (CAS) and advanced membrane bioreactor (MBR) treatment. | Water research 20090201 |
| Fibrates: where are we now? | Therapeutic advances in cardiovascular disease 20090201 |
| Effect of combination nicotinic acid and gemfibrozil treatment on intermediate density lipoprotein, and subclasses of low density lipoprotein and high density lipoprotein in patients with combined hyperlipidemia. | The American journal of cardiology 20090201 |
| Effects of diet and gemfibrozil on posttransplant hyperlipidemia in renal transplant recipients. | Journal of investigative medicine : the official publication of the American Federation for Clinical Research 20090201 |
| Increase in tiagabine serum concentration with coadministration of gemfibrozil. | The Annals of pharmacotherapy 20090201 |
| Pharmaceuticals and endocrine disrupting compounds in U.S. drinking water. | Environmental science & technology 20090201 |
| Evaluation of the acute, chronic and teratogenic effects of a mixture of eleven pharmaceuticals on the cnidarian, Hydra attenuata. | The Science of the total environment 20090115 |
| Syntheses and evaluation of glucosyl aryl thiosemicarbazide and glucosyl thiosemicarbazone derivatives as antioxidant and anti-dyslipidemic agents. | Bioorganic & medicinal chemistry letters 20090115 |
| Prediction of drug clearance by glucuronidation from in vitro data: use of combined cytochrome P450 and UDP-glucuronosyltransferase cofactors in alamethicin-activated human liver microsomes. | Drug metabolism and disposition: the biological fate of chemicals 20090101 |
| Determination of phenolic endocrine disrupting chemicals and acidic pharmaceuticals in surface water of the Pearl Rivers in South China by gas chromatography-negative chemical ionization-mass spectrometry. | The Science of the total environment 20090101 |
| Does nicotinic acid (niacin) lower blood pressure? | International journal of clinical practice 20090101 |
| Prevention and treatment of atherosclerosis: a practitioner's guide for 2008. | The American journal of medicine 20090101 |
| Standards of medical care in diabetes--2009. | Diabetes care 20090101 |
| Multiple splice defects in ABCA1 cause low HDL-C in a family with hypoalphalipoproteinemia and premature coronary disease. | BMC medical genetics 20090101 |
| Augmented lung inflammation protects against influenza A pneumonia. | PloS one 20090101 |
| Pharmspresso: a text mining tool for extraction of pharmacogenomic concepts and relationships from full text. | BMC bioinformatics 20090101 |
| Association between change in high density lipoprotein cholesterol and cardiovascular disease morbidity and mortality: systematic review and meta-regression analysis. | BMJ (Clinical research ed.) 20090101 |
| Life-cycle exposure of fathead minnows to a mixture of six common pharmaceuticals and triclosan. | Journal of toxicology and environmental health. Part A 20090101 |
| MBX-102/JNJ39659100, a novel non-TZD selective partial PPAR-γ agonist lowers triglyceride independently of PPAR-α activation. | PPAR research 20090101 |
| Efficacy and safety of rosuvastatin in the management of dyslipidemia. | Vascular health and risk management 20090101 |
| Management of complex lipid abnormalities with a fixed dose combination of simvastatin and extended release niacin. | Vascular health and risk management 20090101 |
| Dyslipidemia treatment of patients with diabetes mellitus in a US managed care plan: a retrospective database analysis. | Cardiovascular diabetology 20090101 |
| Safety and efficacy of rosiglitazone in the elderly diabetic patient. | Vascular health and risk management 20090101 |
| Lactic acid bacteria affect serum cholesterol levels, harmful fecal enzyme activity, and fecal water content. | Lipids in health and disease 20090101 |
| [Fibrate-induced deterioration of renal function]. | Nefrologia : publicacion oficial de la Sociedad Espanola Nefrologia 20090101 |
| Effects of cardiovascular lifestyle change on lipoprotein subclass profiles defined by nuclear magnetic resonance spectroscopy. | Lipids in health and disease 20090101 |
| Kidney function and estimated vascular risk in patients with primary dyslipidemia. | The open cardiovascular medicine journal 20090101 |
| Regulation of bile acid and cholesterol metabolism by PPARs. | PPAR research 20090101 |
| New options in the treatment of lipid disorders in HIV-infected patients. | The open AIDS journal 20090101 |
| Regulation of sulfotransferase and UDP-glucuronosyltransferase gene expression by the PPARs. | PPAR research 20090101 |
| Gemfibrozil, stretching arms beyond lipid lowering. | Immunopharmacology and immunotoxicology 20090101 |
| Peroxisome proliferator-activated receptor agonists: do they increase cardiovascular risk? | PPAR research 20090101 |
| Lipoprotein ratios: Physiological significance and clinical usefulness in cardiovascular prevention. | Vascular health and risk management 20090101 |
| Drugs associated with more suicidal ideations are also associated with more suicide attempts. | PloS one 20090101 |
| Thinking beyond low-density lipoprotein cholesterol: strategies to further reduce cardiovascular risk. | Vascular health and risk management 20090101 |
| Post-transplant diabetes mellitus. | Diabetology & metabolic syndrome 20090101 |
| A 60-year-old man with chronic renal failure and a costal mass: a case report and review of the literature. | Journal of medical case reports 20090101 |
| Candidate genetic analysis of plasma high-density lipoprotein-cholesterol and severity of coronary atherosclerosis. | BMC medical genetics 20090101 |
| Serum and erythrocyte membrane phospholipids fatty acid composition in hyperlipidemia: effects of dietary intervention and combined diet and fibrate therapy. | General physiology and biophysics 20090101 |
| Plasmapheresis in a patient with rhabdomyolysis: a case report. | Cases journal 20090101 |
| Ciprofibrate increases cholesteryl ester transfer protein gene expression and the indirect reverse cholesterol transport to the liver. | Lipids in health and disease 20090101 |
| Treatment of hypertriglyceridemia and HIV: fenofibrate-induced changes in the expression of chemokine genes in circulating leukocytes. | AIDS research and therapy 20090101 |
| Membrane omega-3 Fatty Acid deficiency as a preventable risk factor for comorbid coronary heart disease in major depressive disorder. | Cardiovascular psychiatry and neurology 20090101 |
| Management of dyslipidemia in children. | Diabetology & metabolic syndrome 20090101 |
| Critical appraisal of the role of pitavastatin in treating dyslipidemias and achieving lipid goals. | Vascular health and risk management 20090101 |
| Pharmacokinetic Study of a Novel Antihyperlipidemic Agent LM-13765- A Prodrug. | Indian journal of pharmaceutical sciences 20090101 |
| Raising HDL cholesterol in women. | International journal of women's health 20090101 |
| Alogliptin: a new addition to the class of DPP-4 inhibitors. | Diabetes, metabolic syndrome and obesity : targets and therapy 20090101 |
| Expert perspective: reducing cardiovascular risk in metabolic syndrome and type 2 diabetes mellitus beyond low-density lipoprotein cholesterol lowering. | The American journal of cardiology 20081222 |
| Severe acute renal failure following high-dose methotrexate therapy in adults with haematological malignancies: a significant number result from unrecognized co-administration of several drugs. | Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association 20081201 |
| Novel peroxisome proliferator-activated receptor alpha agonists lower low-density lipoprotein and triglycerides, raise high-density lipoprotein, and synergistically increase cholesterol excretion with a liver X receptor agonist. | The Journal of pharmacology and experimental therapeutics 20081201 |
| Diplopia, blepharoptosis, and ophthalmoplegia and 3-hydroxy-3-methyl-glutaryl-CoA reductase inhibitor use. | Ophthalmology 20081201 |
| Determination of pharmaceuticals in drinking water by CD-modified MEKC: separation optimization using experimental design. | Journal of separation science 20081201 |
| Effect of extended-release niacin on hormone-sensitive lipase and lipoprotein lipase in patients with HIV-associated lipodystrophy syndrome. | Biologics : targets & therapy 20081201 |
| Rosuvastatin reduces non-high-density lipoprotein cholesterol and lipoprotein remnants in patients with dysbetalipoproteinemia (Fredrickson type III hyperlipoproteinemia). | Journal of clinical lipidology 20081201 |
| Quantitative structure-activity relationship and complex network approach to monoamine oxidase A and B inhibitors. | Journal of medicinal chemistry 20081113 |
| Novel keto-enamine Schiffs bases from 7-hydroxy-4-methyl-2-oxo-2H-benzo[h] chromene-8,10-dicarbaldehyde as potential antidyslipidemic and antioxidant agents. | European journal of medicinal chemistry 20081101 |
| Advances in stir bar sorptive extraction for the determination of acidic pharmaceuticals in environmental water matrices Comparison between polyurethane and polydimethylsiloxane polymeric phases. | Journal of chromatography. A 20081031 |
| Design, synthesis, and biological evaluation of novel constrained meta-substituted phenyl propanoic acids as peroxisome proliferator-activated receptor alpha and gamma dual agonists. | Journal of medicinal chemistry 20081023 |
| To statin or to non-statin in coronary disease-considering absolute risk is the answer. | Atherosclerosis 20081001 |
| Correlation between plasma levels of 7alpha-hydroxy-4-cholesten-3-one and cholesterol 7alpha-hydroxylation rates in vivo in hyperlipidemic patients. | Steroids 20081001 |
| Triglycerides and risk for coronary artery disease. | Current atherosclerosis reports 20081001 |
| Biodegradation of acidic pharmaceuticals in bed sediments: insight from a laboratory experiment. | Environmental science & technology 20081001 |
| Update on the clinical utility of fenofibrate in mixed dyslipidemias: mechanisms of action and rational prescribing. | Vascular health and risk management 20081001 |
| Targeting multiple dyslipidemias with fixed combinations--focus on extended release niacin and simvastatin. | Vascular health and risk management 20081001 |
| Effects of gemfibrozil and atorvastatin on the pharmacokinetics of repaglinide in relation to SLCO1B1 polymorphism. | Clinical pharmacology and therapeutics 20081001 |
| The effect of gemfibrozil on repaglinide pharmacokinetics persists for at least 12 h after the dose: evidence for mechanism-based inhibition of CYP2C8 in vivo. | Clinical pharmacology and therapeutics 20080901 |
| Application of software design principles and debugging methods to an analgesia prescription reduces risk of severe injury from medical use of opioids. | Clinical pharmacology and therapeutics 20080901 |
| Confronting an influenza pandemic with inexpensive generic agents: can it be done? | The Lancet. Infectious diseases 20080901 |
| Investigation on different levels of in vitro-in vivo correlation: gemfibrozil immediate release capsule. | Biopharmaceutics & drug disposition 20080901 |
| The effects of pharmaceuticals on the regeneration of the cnidarian, Hydra attenuata. | The Science of the total environment 20080825 |
| A toxicogenomics approach for early assessment of potential non-genotoxic hepatocarcinogenicity of chemicals in rats. | Toxicology 20080819 |
| Efficacy and safety of a potent and selective peroxisome proliferator activated receptor alpha agonist in subjects with dyslipidemia and type 2 diabetes mellitus. | The American journal of cardiology 20080815 |
| Micronization of gemfibrozil by reactive precipitation process. | International journal of pharmaceutics 20080806 |
| Analysis of the complexation of gemfibrozil with gamma- and hydroxypropyl-gamma-cyclodextrins. | Journal of pharmaceutical and biomedical analysis 20080805 |
| Effects of statins on high-density lipoproteins: a potential contribution to cardiovascular benefit. | Cardiovascular drugs and therapy 20080801 |
| Rejection of pharmaceuticals in nanofiltration and reverse osmosis membrane drinking water treatment. | Water research 20080801 |
| Genomic profiling reveals an alternate mechanism for hepatic tumor promotion by perfluorooctanoic acid in rainbow trout. | Environmental health perspectives 20080801 |
| Familial dysbetalipoproteinemia: a potentially fatal disorder. | Journal of the College of Physicians and Surgeons--Pakistan : JCPSP 20080801 |
| The Relationship Between HIV Infection and Cardiovascular Disease. | Current cardiology reviews 20080801 |
| Characterization of the drug binding specificity of rat liver fatty acid binding protein. | Journal of medicinal chemistry 20080710 |
| An unusual case of familial hyperlipidaemia. | Indian journal of clinical biochemistry : IJCB 20080701 |
| The occurrence of acidic drugs and caffeine in sewage effluents and receiving waters from three coastal watersheds in Atlantic Canada. | The Science of the total environment 20080625 |
| Runoff of pharmaceuticals and personal care products following application of biosolids to an agricultural field. | The Science of the total environment 20080615 |
| Cardiovascular events with increased lipoprotein-associated phospholipase A(2) and low high-density lipoprotein-cholesterol: the Veterans Affairs HDL Intervention Trial. | Arteriosclerosis, thrombosis, and vascular biology 20080601 |
| Use of biodegradable dissolved organic carbon (BDOC) to assess the potential for transformation of wastewater-derived contaminants in surface waters. | Water research 20080601 |
| Efficacy of lipid-lowering medications in patients treated with clozapine: a naturalistic study. | Journal of clinical psychopharmacology 20080601 |
| Mortality in COPD: inevitable or preventable? Insights from the cardiovascular arena. | COPD 20080601 |
| In vitro evaluation of reversible and irreversible cytochrome P450 inhibition: current status on methodologies and their utility for predicting drug-drug interactions. | The AAPS journal 20080601 |
| Atorvastatin and cardiovascular risk in the elderly--patient considerations. | Clinical interventions in aging 20080601 |
| Relative safety profiles of high dose statin regimens. | Vascular health and risk management 20080601 |
| Multiple inhibition mechanisms and prediction of drug-drug interactions: status of metabolism and transporter models as exemplified by gemfibrozil-drug interactions. | Pharmaceutical research 20080501 |
| Pharmaceutical particle engineering via spray drying. | Pharmaceutical research 20080501 |
| The excitation-contraction coupling on C2C12 skeletal muscle myotubes was modulated by NO-donor ester of gemfibrozil. | Nitric oxide : biology and chemistry 20080501 |
| Obesity and hypertriglyceridemia produce cognitive impairment. | Endocrinology 20080501 |
| Clofibrate and gemfibrozil induce an embryonic malabsorption syndrome in zebrafish. | Toxicology and applied pharmacology 20080501 |
| Effectiveness of lipid-lowering therapy in HIV patients. | Current opinion in HIV and AIDS 20080501 |
| Inhibiting wild-type and C299S mutant AKR1B10; a homologue of aldose reductase upregulated in cancers. | European journal of pharmacology 20080428 |
| Fate of pharmaceutical and trace organic compounds in three septic system plumes, Ontario, Canada. | Environmental science & technology 20080415 |
| Concentrations and mobility of human pharmaceuticals in the world's largest wastewater irrigation system, Mexico City-Mezquital Valley. | Water research 20080401 |
| Differential effects of fibrates on the metabolic activation of 2-phenylpropionic acid in rats. | Drug metabolism and disposition: the biological fate of chemicals 20080401 |
| The peroxisome: still a mysterious organelle. | Histochemistry and cell biology 20080401 |
| Belgian expert opinion: how to reduce the residual risk in atherogenic dyslipidaemic patients: place of fibrates. | Acta cardiologica 20080401 |
| Combination therapy in cholesterol reduction: focus on ezetimibe and statins. | Vascular health and risk management 20080401 |
| Clinical efficacy and safety of statins in managing cardiovascular risk. | Vascular health and risk management 20080401 |
| A pilot study in the efficacy and safety of gemfibrozil in a pediatric population. | Journal of clinical lipidology 20080401 |
| Effects of fibrate drugs on expression of ABCA1 and HDL biogenesis in hepatocytes. | Journal of cardiovascular pharmacology 20080301 |
| [Prescription patterns for antilipidemic drugs in a group of Colombian patients]. | Revista panamericana de salud publica = Pan American journal of public health 20080301 |
| Vascular and metabolic effects of treatment of combined hyperlipidemia: focus on statins and fibrates. | International journal of cardiology 20080227 |
| Phytotoxicity evaluation of five pharmaceutical pollutants detected in surface water on germination and growth of cultivated and spontaneous plants. | Journal of environmental science and health. Part A, Toxic/hazardous substances & environmental engineering 20080215 |
| Body weight, plasma insulin, and coronary events with gemfibrozil in the Veterans Affairs High-Density Lipoprotein Intervention Trial (VA-HIT). | Atherosclerosis 20080201 |
| The effect of suspended particles coated by humic acid on the toxicity of pharmaceuticals, estrogens, and phenolic compounds. | Environment international 20080201 |
| The economic consequences of noncompliance in cardiovascular disease and related conditions: a literature review. | International journal of clinical practice 20080201 |
| Management of mixed dyslipidemia in patients with or at risk for cardiovascular disease: a role for combination fibrate therapy. | Clinical therapeutics 20080201 |
| Does the addition of fibrates to statin therapy have a favorable risk to benefit ratio? | Current atherosclerosis reports 20080201 |
| Update on the use of fibrates: focus on bezafibrate. | Vascular health and risk management 20080201 |
| High density lipoprotein cholesterol: an evolving target of therapy in the management of cardiovascular disease. | Vascular health and risk management 20080201 |
| A hazardous finding of a rare anomalous left main coronary artery in a patient with a secundum atrial septal defect. | Vascular health and risk management 20080201 |
| An investigation into the acute and chronic toxicity of eleven pharmaceuticals (and their solvents) found in wastewater effluent on the cnidarian, Hydra attenuata. | The Science of the total environment 20080125 |
| Influence of gemfibrozil on sulfate transport in human erythrocytes during the oxygenation-deoxygenation cycle. | Physiological research 20080101 |
| Is there a role for fibrates in the management of dyslipidemia in the metabolic syndrome? | Arteriosclerosis, thrombosis, and vascular biology 20080101 |
| Peroxisome proliferator-activated receptors--from active regulators of macrophage biology to pharmacological targets in the treatment of cardiovascular disease. | Journal of internal medicine 20080101 |
| Relation of gemfibrozil treatment and high-density lipoprotein subpopulation profile with cardiovascular events in the Veterans Affairs High-Density Lipoprotein Intervention Trial. | Metabolism: clinical and experimental 20080101 |
| Peroxisome proliferator-activated receptors (PPARs) and the human skin: importance of PPARs in skin physiology and dermatologic diseases. | American journal of clinical dermatology 20080101 |
| Relative safety of gemfibrozil and fenofibrate in the absence of concomitant cerivastatin use. | The American journal of cardiology 20080101 |
| Incidence of adverse events with HMG-CoA reductase inhibitors in liver transplant patients. | Clinical transplantation 20080101 |
| Effect of chemosensitizers on minimum inhibitory concentrations of fluconazole in Candida albicans. | Medical principles and practice : international journal of the Kuwait University, Health Science Centre 20080101 |
| Peroxisome proliferator activated receptors and lipoprotein metabolism. | PPAR research 20080101 |
| PPAR Agonists and Cardiovascular Disease in Diabetes. | PPAR research 20080101 |
| The PPAR-Platelet Connection: Modulators of Inflammation and Potential Cardiovascular Effects. | PPAR research 20080101 |
| Should We Use PPAR Agonists to Reduce Cardiovascular Risk? | PPAR research 20080101 |
| Effect of synthetic dietary triglycerides: a novel research paradigm for nutrigenomics. | PloS one 20080101 |
| Frequency and clinical relevance of drug interactions with lovastatin and simvastatin: an observational database study. | Drug safety 20080101 |
| Fosamprenavir or atazanavir once daily boosted with ritonavir 100 mg, plus tenofovir/emtricitabine, for the initial treatment of HIV infection: 48-week results of ALERT. | AIDS research and therapy 20080101 |
| PPAR-gamma, Microglial Cells, and Ocular Inflammation: New Venues for Potential Therapeutic Approaches. | PPAR research 20080101 |
| PPAR Genomics and Pharmacogenomics: Implications for Cardiovascular Disease. | PPAR research 20080101 |
| PPAR-alpha Ligands as Potential Therapeutic Agents for Wet Age-Related Macular Degeneration. | PPAR research 20080101 |
| PPARs and Female Reproduction: Evidence from Genetically Manipulated Mice. | PPAR research 20080101 |
| Hypertriglyceridemia and hypercholesterolemia: effects of drug treatment on fatty acid composition of plasma lipids and membranes. | Prostaglandins, leukotrienes, and essential fatty acids 20080101 |
| Plasma PCSK9 levels are significantly modified by statins and fibrates in humans. | Lipids in health and disease 20080101 |
| Peroxisome proliferator-activated receptors and progression of colorectal cancer. | PPAR research 20080101 |
| Pharmacokinetic comparison of the potential over-the-counter statins simvastatin, lovastatin, fluvastatin and pravastatin. | Clinical pharmacokinetics 20080101 |
| Peroxisome Proliferators-Activated Receptor (PPAR) Modulators and Metabolic Disorders. | PPAR research 20080101 |
| Statin induced myopathy and myalgia: time trend analysis and comparison of risk associated with statin class from 1991-2006. | PloS one 20080101 |
| [Rosuvastatin for the treatment of dyslipidemia in HIV-infected patients receiving highly active antiretroviral therapy. Preliminary experience]. | Enfermedades infecciosas y microbiologia clinica 20080101 |
| Mitochondria, PPARs, and Cancer: Is Receptor-Independent Action of PPAR Agonists a Key? | PPAR research 20080101 |
| PPAR Alpha Regulation of the Immune Response and Autoimmune Encephalomyelitis. | PPAR research 20080101 |
| PPAR Ligands as Potential Modifiers of Breast Carcinoma Outcomes. | PPAR research 20080101 |
| Role of peroxisome proliferator-activated receptor alpha in the control of cyclooxygenase 2 and vascular endothelial growth factor: involvement in tumor growth. | PPAR research 20080101 |
| PPAR Regulation of Inflammatory Signaling in CNS Diseases. | PPAR research 20080101 |
| PPARalpha Ligands as Antitumorigenic and Antiangiogenic Agents. | PPAR research 20080101 |
| Pioglitazone versus Rosiglitazone: Effects on Lipids, Lipoproteins, and Apolipoproteins in Head-to-Head Randomized Clinical Studies. | PPAR research 20080101 |
| Oxidative effects of gemfibrozil on anion influx and metabolism in normal and Beta-thalassemic erythrocytes: physiological implications. | The Journal of membrane biology 20080101 |
| Removal of selected pharmaceuticals by chlorination, coagulation-sedimentation and powdered activated carbon treatment. | Water science and technology : a journal of the International Association on Water Pollution Research 20080101 |
| Low HDL cholesterol, smoking and IL-13 R130Q polymorphism are associated with myocardial infarction in Greek Cypriot males. A pilot study. | The open cardiovascular medicine journal 20080101 |
| Statins but not fibrates improve the atherogenic to anti-atherogenic lipoprotein particle ratio: a randomized crossover study. | BMC clinical pharmacology 20080101 |
| Feeding mice with diets containing mercury-contaminated fish flesh from French Guiana: a model for the mercurial intoxication of the Wayana Amerindians. | Environmental health : a global access science source 20080101 |
| PPAR-delta in Vascular Pathophysiology. | PPAR research 20080101 |
| Preformulative assessment of preformed complexes of gemfibrozil, with cyclodextrins. | PDA journal of pharmaceutical science and technology 20080101 |
| The Role of NF-kappaB in PPARalpha-Mediated Hepatocarcinogenesis. | PPAR research 20080101 |
| Peroxisome proliferator-activated receptors in diabetic nephropathy. | PPAR research 20080101 |
| Effect of Chlorella vulgaris on lipid metabolism in Wistar rats fed high fat diet. | Nutrition research and practice 20080101 |
| Induction of nuclear translocation of constitutive androstane receptor by peroxisome proliferator-activated receptor alpha synthetic ligands in mouse liver. | The Journal of biological chemistry 20071214 |
| How useful are prescribing indicators based on the DU90% method to distinguish the quality of prescribing between pharmacotherapy audit meetings with different levels of functioning? | European journal of clinical pharmacology 20071201 |
| Fenofibrate inhibits intestinal Cl- secretion by blocking basolateral KCNQ1 K+ channels. | American journal of physiology. Gastrointestinal and liver physiology 20071201 |
| Gemfibrozil ingestions reported to Texas poison control centers, 2000-2005. | Journal of toxicology and environmental health. Part A 20071201 |
| Prediction of the metabolic interaction of nateglinide with other drugs based on in vitro studies. | Drug metabolism and pharmacokinetics 20071201 |
| Practical guidelines for familial combined hyperlipidemia diagnosis: an up-date. | Vascular health and risk management 20071201 |
| Shift work, occupational noise and physical workload with ensuing development of blood pressure and their joint effect on the risk of coronary heart disease. | Scandinavian journal of work, environment & health 20071201 |
| Treatment of non-alcoholic fatty liver disease. | Therapeutics and clinical risk management 20071201 |
| Myelin basic protein-primed T cells induce neurotrophins in glial cells via alphavbeta3 [corrected] integrin. | The Journal of biological chemistry 20071102 |
| To statin or to non-statin in coronary disease--considering absolute risk is the answer. | Atherosclerosis 20071101 |
| Increased atherosclerosis following treatment with a dual PPAR agonist in the ApoE knockout mouse. | Atherosclerosis 20071101 |
| The UDP-glucuronosyltransferase 2B7 isozyme is responsible for gemfibrozil glucuronidation in the human liver. | Drug metabolism and disposition: the biological fate of chemicals 20071101 |
| Variations in bioconcentration of human pharmaceuticals from sewage effluents into fish blood plasma. | Environmental toxicology and pharmacology 20071101 |
| Risk of congenital anomalies in pregnant users of statin drugs. | British journal of clinical pharmacology 20071001 |
| Effects of blood lipid lowering pharmaceuticals (bezafibrate and gemfibrozil) on immune and digestive gland functions of the bivalve mollusc, Mytilus galloprovincialis. | Chemosphere 20071001 |
| Gemfibrozil ameliorates relapsing-remitting experimental autoimmune encephalomyelitis independent of peroxisome proliferator-activated receptor-alpha. | Molecular pharmacology 20071001 |
| Gene expression profiling of rat liver treated with serum triglyceride-decreasing compounds. | The Journal of toxicological sciences 20071001 |
| Colesevelam hydrochloride: reducing atherosclerotic coronary heart disease risk factors. | Vascular health and risk management 20071001 |
| Mitochondrial impairment by PPAR agonists and statins identified via immunocaptured OXPHOS complex activities and respiration. | Toxicology and applied pharmacology 20070915 |
| Involvement of phosphatidylinositol 3-kinase-mediated up-regulation of I kappa B alpha in anti-inflammatory effect of gemfibrozil in microglia. | Journal of immunology (Baltimore, Md. : 1950) 20070915 |
| Codon 54 polymorphism of the fatty acid binding protein (FABP) 2 gene is associated with increased cardiovascular risk in the dyslipidemic diabetic participants of the Veterans Affairs HDL intervention trial (VA-HIT). | Atherosclerosis 20070901 |
| Simvastatin: present and future perspectives. | Expert opinion on pharmacotherapy 20070901 |
| The clinical relevance of LDL size and subclasses modulation in patients with type-2 diabetes. | Experimental and clinical endocrinology & diabetes : official journal, German Society of Endocrinology [and] German Diabetes Association 20070901 |
| Use of lipid-modulating drugs in complicated course of coronary heart disease. | Bulletin of experimental biology and medicine 20070901 |
| Cheaper approaches to flu divide researchers. | Nature 20070830 |
| Endothelial NF-kappaB as a mediator of kidney damage: the missing link between systemic vascular and renal disease? | Circulation research 20070803 |
| Atorvastatin glucuronidation is minimally and nonselectively inhibited by the fibrates gemfibrozil, fenofibrate, and fenofibric acid. | Drug metabolism and disposition: the biological fate of chemicals 20070801 |
| Substrate-dependent drug-drug interactions between gemfibrozil, fluvastatin and other organic anion-transporting peptide (OATP) substrates on OATP1B1, OATP2B1, and OATP1B3. | Drug metabolism and disposition: the biological fate of chemicals 20070801 |
| Influence of HDL-cholesterol-elevating drugs on the in vitro activity of the HDL receptor SR-BI. | Journal of lipid research 20070801 |
| Wastewater treatment plants as a pathway for aquatic contamination by pharmaceuticals in the ebro river basin (northeast Spain). | Environmental toxicology and chemistry 20070801 |
| Prolonged-release nicotinic acid for the management of dyslipidemia: an update including results from the NAUTILUS study. | Vascular health and risk management 20070801 |
| Mitochondria, ciglitazone and liver: a neglected interaction in biochemical pharmacology. | European journal of pharmacology 20070712 |
| Toxic and genotoxic impact of fibrates and their photoproducts on non-target organisms. | Environment international 20070701 |
| Expeditious and convenient synthesis of pregnanes and its glycosides as potential anti-dyslipidemic and anti-oxidant agents. | Bioorganic & medicinal chemistry 20070701 |
| Design, synthesis, and structure-activity relationship of carbamate-tethered aryl propanoic acids as novel PPARalpha/gamma dual agonists. | Bioorganic & medicinal chemistry letters 20070701 |
| Electrokinetic migration of acidic drugs across a supported liquid membrane. | Journal of chromatography. A 20070608 |
| Analytical development for analysis of pharmaceuticals in water samples by SPE and GC-MS. | Analytical and bioanalytical chemistry 20070601 |
| A randomized trial of the effect of statin and fibrate therapy on arterial function in CKD. | American journal of kidney diseases : the official journal of the National Kidney Foundation 20070601 |
| [High sensitivity of C-reactive protein in primary prevention]. | Giornale italiano di cardiologia (2006) 20070601 |
| Stereoselective interaction between the CYP2C8 inhibitor gemfibrozil and racemic ibuprofen. | European journal of clinical pharmacology 20070501 |
| The clinical significance of the size of low-density-lipoproteins and the modulation of subclasses by fibrates. | Current medical research and opinion 20070501 |
| Gemfibrozil and its glucuronide inhibit the hepatic uptake of pravastatin mediated by OATP1B1. | Xenobiotica; the fate of foreign compounds in biological systems 20070501 |
| Cholesterol reduction yields clinical benefits: meta-analysis including recent trials. | Clinical therapeutics 20070501 |
| Optimizing gas chromatographic-mass spectrometric analysis of selected pharmaceuticals and endocrine-disrupting substances in water using factorial experimental design. | Journal of chromatography. A 20070427 |
| Inhibition of human organic anion transporter 3 mediated pravastatin transport by gemfibrozil and the metabolites in humans. | Xenobiotica; the fate of foreign compounds in biological systems 20070401 |
| Safety considerations with fibrate therapy. | The American journal of cardiology 20070319 |
| Risk factors for statin-associated rhabdomyolysis. | Pharmacoepidemiology and drug safety 20070301 |
| PPAR alpha agonists improve renal preservation in kidneys subjected to chronic in vitro perfusion: interaction with mannitol. | Transplant international : official journal of the European Society for Organ Transplantation 20070301 |
| Fibrates: what have we learned in the past 40 years? | Pharmacotherapy 20070301 |
| Neuropsychiatric consequences of cardiovascular medications. | Dialogues in clinical neuroscience 20070301 |
| Effect of drugs on high-density lipoprotein. | Journal of clinical lipidology 20070301 |
| Toxicological effects of the lipid regulator gemfibrozil in four aquatic systems. | Aquatic toxicology (Amsterdam, Netherlands) 20070215 |
| Analysis of pharmaceuticals in wastewater and removal using a membrane bioreactor. | Analytical and bioanalytical chemistry 20070201 |
| Polar herbicides, pharmaceutical products, perfluorooctanesulfonate (PFOS), perfluorooctanoate (PFOA), and nonylphenol and its carboxylates and ethoxylates in surface and tap waters around Lake Maggiore in Northern Italy. | Analytical and bioanalytical chemistry 20070201 |
| Tamoxifen and hypertriglyceridaemia. | Prescrire international 20070201 |
| Human pharmaceuticals, antioxidants, and plasticizers in wastewater treatment plant and water reclamation plant effluents. | Water environment research : a research publication of the Water Environment Federation 20070201 |
| Effect of lipid-lowering and anti-hypertensive drugs on plasma homocysteine levels. | Vascular health and risk management 20070201 |
| Vascular wall proteoglycan synthesis and structure as a target for the prevention of atherosclerosis. | Vascular health and risk management 20070201 |
| Chylous ascites secondary to hyperlipidemic pancreatitis with normal serum amylase and lipase. | World journal of gastroenterology 20070121 |
| A simple in vitro model to study the stability of acylglucuronides. | Journal of pharmacological and toxicological methods 20070101 |
| Effect of a mixture of seven pharmaceuticals on Hyalella azteca over multiple generations. | Chemosphere 20070101 |
| Therapeutic approach to FSGS in children. | Pediatric nephrology (Berlin, Germany) 20070101 |
| Combined organ failure with combination antihyperlipidemic treatment: a case of hepatic injury and acute renal failure. | The Annals of pharmacotherapy 20070101 |
| Pharmacokinetic interactions with thiazolidinediones. | Clinical pharmacokinetics 20070101 |
| Drug-drug and food-drug pharmacokinetic interactions with new insulinotropic agents repaglinide and nateglinide. | Clinical pharmacokinetics 20070101 |
| Safety of rosuvastatin: update on 16,876 rosuvastatin-treated patients in a multinational clinical trial program. | Cardiology 20070101 |
| Use of statins and gemfibrozil in patients with type 2 diabetes mellitus and cardiovascular risk factors attending adult day health care centers: an opportunity for pharmacists. | The Consultant pharmacist : the journal of the American Society of Consultant Pharmacists 20070101 |
| PPARs, Obesity, and Inflammation. | PPAR research 20070101 |
| Risk and predictability of drug interactions in the elderly. | International review of neurobiology 20070101 |
| Therapeutic potential of retinoid x receptor modulators for the treatment of the metabolic syndrome. | PPAR research 20070101 |
| Therapeutic rationale of combining therapy with gemfibrozil and simvastatin. | Journal of the American Pharmacists Association : JAPhA 20070101 |
| Pharmacokinetic comparisons of tail-bleeding with cannula- or retro-orbital bleeding techniques in rats using six marketed drugs. | Journal of pharmacological and toxicological methods 20070101 |
| Atypical presentation of a middle age male with severe hypertriglyceridaemia: a case report. | Journal of medical case reports 20070101 |
| HIV-associated adipose redistribution syndrome (HARS): definition, epidemiology and clinical impact. | AIDS research and therapy 20070101 |
| Cardiovascular benefits and safety profile of acarbose therapy in prediabetes and established type 2 diabetes. | Cardiovascular diabetology 20070101 |
| The Role of PPARs in Lung Fibrosis. | PPAR research 20070101 |
| An investigation of the effects of lipid-lowering medications: genome-wide linkage analysis of lipids in the HyperGEN study. | BMC genetics 20070101 |
| PPARs and diabetes-associated atherosclerosis. | Current pharmaceutical design 20070101 |
| Are HIV positive patients resistant to statin therapy? | Lipids in health and disease 20070101 |
| Fish-oil esters of plant sterols differ from vegetable-oil sterol esters in triglycerides lowering, carotenoid bioavailability and impact on plasminogen activator inhibitor-1 (PAI-1) concentrations in hypercholesterolemic subjects. | Lipids in health and disease 20070101 |
| Synthesis and antihyperlipidemic activity of some novel condensed 2-chloroalkyl-4-chloro/hydroxy-5,6-disubstituted pyrimidines. | Arzneimittel-Forschung 20070101 |
| Palmar erythema. | American journal of clinical dermatology 20070101 |
| Peroxisome proliferators-activated alpha agonist treatment ameliorates hepatic damage in rats with obstructive jaundice: an experimental study. | BMC gastroenterology 20070101 |
| The Functions of PPARs in Aging and Longevity. | PPAR research 20070101 |
| Phthalate-Induced Liver Protection against Deleterious Effects of the Th1 Response: A Potentially Serious Health Hazard. | PPAR research 20070101 |
| Solubilizing properties of new surface-active agents, products of selective oxyethylation of cholic acid. Part I. | Polimery w medycynie 20070101 |
| Statin-Induced Increase in HDL-C and Renal Function in Coronary Heart Disease Patients. | The open cardiovascular medicine journal 20070101 |
| Hypertriglyceridemia and Recurrent Pancreatitis following Splenectomy. | Case reports in gastroenterology 20070101 |
| Waterborne gemfibrozil challenges the hepatic antioxidant defense system and down-regulates peroxisome proliferator-activated receptor beta (PPARbeta) mRNA levels in male goldfish (Carassius auratus). | Toxicology 20061207 |
| Simultaneous low-density lipoprotein-C lowering and high-density lipoprotein-C elevation for optimum cardiovascular disease prevention with various drug classes, and their combinations: a meta-analysis of 23 randomized lipid trials. | Current opinion in lipidology 20061201 |
| Reproducible tendinitis-like symptoms related to statin therapy. | Journal of clinical rheumatology : practical reports on rheumatic & musculoskeletal diseases 20061201 |
| Fibrates after the FIELD study: Some answers, more questions. | Diabetes & vascular disease research 20061201 |
| Nicotinic acid: new/old drug. Immediate or sustained release: too risky for a drug with no proven benefit. | Prescrire international 20061201 |
| Drug interactions with lipid-lowering drugs: mechanisms and clinical relevance. | Clinical pharmacology and therapeutics 20061201 |
| Organic anion transporting polypeptide 2B1 is a high-affinity transporter for atorvastatin and is expressed in the human heart. | Clinical pharmacology and therapeutics 20061201 |
| Attenuation of wastewater-derived contaminants in an effluent-dominated river. | Environmental science & technology 20061201 |
| Utilization of a one-dimensional score for surveying chemical-induced changes in expression levels of multiple biomarker gene sets using a large-scale toxicogenomics database. | The Journal of toxicological sciences 20061201 |
| Profiling of gene expression in rat liver and rat primary cultured hepatocytes treated with peroxisome proliferators. | The Journal of toxicological sciences 20061201 |
| Management of hyperlipidemia with statins in the older patient. | Clinical interventions in aging 20061201 |
| Simultaneous quantitation of rosuvastatin and gemfibrozil in human plasma by high-performance liquid chromatography and its application to a pharmacokinetic study. | Biomedical chromatography : BMC 20061101 |
| Statins, fibrates, and melanoma risk: a systematic review and meta-analysis. | Journal of the National Cancer Institute 20061101 |
| Long term clinical trials: how much information do participants retain from the informed consent process? | Contemporary clinical trials 20061001 |
| [Gemfibrozil induced rhabdomyolysis in a patient with undiscovered hypothyroidism]. | Anales de medicina interna (Madrid, Spain : 1984) 20061001 |
| Peroxisome proliferator-activated receptors increase human sebum production. | The Journal of investigative dermatology 20060901 |
| PPAR-alpha and -gamma agonists attenuate diabetic kidney disease in the apolipoprotein E knockout mouse. | Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association 20060901 |
| Key issues in the modes of action and effects of trichloroethylene metabolites for liver and kidney tumorigenesis. | Environmental health perspectives 20060901 |
| Key issues in the role of peroxisome proliferator-activated receptor agonism and cell signaling in trichloroethylene toxicity. | Environmental health perspectives 20060901 |
| Seasonality effects on pharmaceuticals and s-triazine herbicides in wastewater effluent and surface water from the Canadian side of the upper Detroit River. | Environmental toxicology and chemistry 20060901 |
| Consequences of treated water recycling as regards pharmaceuticals and drugs in surface and ground waters of a medium-sized Mediterranean catchment. | Environmental science & technology 20060901 |
| A review of omega-3 ethyl esters for cardiovascular prevention and treatment of increased blood triglyceride levels. | Vascular health and risk management 20060901 |
| The interference of pharmaceuticals with endogenous and xenobiotic metabolizing enzymes in carp liver: an in-vitro study. | Environmental science & technology 20060815 |
| Agonists of the peroxisome proliferator-activated receptor alpha induce a fiber-type-selective transcriptional response in rat skeletal muscle. | Toxicological sciences : an official journal of the Society of Toxicology 20060801 |
| Managing diabetic dyslipidaemia--beyond LDL-C:HDL-C and triglycerides. | Atherosclerosis. Supplements 20060801 |
| The CYP2C8 inhibitor gemfibrozil does not increase the plasma concentrations of zopiclone. | European journal of clinical pharmacology 20060801 |
| The sense of coherence and incidence of cancer--role of follow-up time and age at baseline. | Journal of psychosomatic research 20060801 |
| It's all connected. | The American journal of medicine 20060801 |
| Occurrence of pharmaceutical products in a municipal effluent and toxicity to rainbow trout (Oncorhynchus mykiss) hepatocytes. | Ecotoxicology and environmental safety 20060701 |
| The L162V polymorphism at the peroxisome proliferator activated receptor alpha locus modulates the risk of cardiovascular events associated with insulin resistance and diabetes mellitus: the Veterans Affairs HDL Intervention Trial (VA-HIT). | Atherosclerosis 20060701 |
| Peroxisome proliferator-activated receptor-alpha and retinoid X receptor agonists inhibit inflammatory responses of astrocytes. | Journal of neuroimmunology 20060701 |
| Peroxisome proliferator-activated receptors in vascular biology-molecular mechanisms and clinical implications. | Vascular pharmacology 20060701 |
| Evaluation of laboratory monitoring alerts within a computerized physician order entry system for medication orders. | The American journal of managed care 20060701 |
| Pioglitazone is metabolised by CYP2C8 and CYP3A4 in vitro: potential for interactions with CYP2C8 inhibitors. | Basic & clinical pharmacology & toxicology 20060701 |
| Effects of selected pharmaceutical products on phagocytic activity in Elliptio complanata mussels. | Comparative biochemistry and physiology. Toxicology & pharmacology : CBP 20060601 |
| Itraconazole, gemfibrozil and their combination markedly raise the plasma concentrations of loperamide. | European journal of clinical pharmacology 20060601 |
| Natural attenuation of pharmaceuticals and alkylphenol polyethoxylate metabolites during river transport: photochemical and biological transformation. | Environmental toxicology and chemistry 20060601 |
| Secondary prevention of ischaemic cardiac events. | Clinical evidence 20060601 |
| Dyslipidaemia in diabetes. | Clinical evidence 20060601 |
| Prevention of cardiovascular events in diabetes. | Clinical evidence 20060601 |
| Metabolic syndrome, inflammation and atherosclerosis. | Vascular health and risk management 20060601 |
| Fenofibrate: a novel formulation (Triglide) in the treatment of lipid disorders: a review. | International journal of nanomedicine 20060601 |
| Determination of acidic drugs and caffeine in municipal wastewaters and receiving waters by gas chromatography-ion trap tandem mass spectrometry. | Journal of chromatography. A 20060526 |
| Separation of fibrate-type antihyperlipidemic drugs by capillary electrophoresis and their quantitation in pharmaceuticals. | Journal of pharmaceutical and biomedical analysis 20060503 |
| Factors influencing the intracellular activity of fluoroquinolones: a study using levofloxacin in a Staphylococcus aureus THP-1 monocyte model. | The Journal of antimicrobial chemotherapy 20060501 |
| Microsphere-based protease assays and screening application for lethal factor and factor Xa. | Cytometry. Part A : the journal of the International Society for Analytical Cytology 20060501 |
| Bioactivation of carboxylic acid compounds by UDP-Glucuronosyltransferases to DNA-damaging intermediates: role of glycoxidation and oxidative stress in genotoxicity. | Chemical research in toxicology 20060501 |
| Statin safety and drug interactions: clinical implications. | The American journal of cardiology 20060417 |
| Statin safety: a systematic review. | The American journal of cardiology 20060417 |
| The role of fibrates in a statin world. | Archives of internal medicine 20060410 |
| Gemfibrozil in the treatment of dyslipidemia: an 18-year mortality follow-up of the Helsinki Heart Study. | Archives of internal medicine 20060410 |
| The role of transporters in drug interactions. | European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences 20060401 |
| Gemfibrozil decreases atherosclerosis in experimental diabetes in association with a reduction in oxidative stress and inflammation. | Diabetologia 20060401 |
| Effects of vitamin E and gemfibrozil on lipid profiles, lipid peroxidation and antioxidant status in the elderly and young hyperlipidemic subjects. | Saudi medical journal 20060401 |
| Meglitinide analogues: a review of clinical data focused on recent trials. | Diabetes & metabolism 20060401 |
| [Fibrate-induced changes in the serum lipid contents of individual C16 and C18 fatty acids in patients with hyperlipidemia]. | Klinicheskaia laboratornaia diagnostika 20060401 |
| Low-density lipoprotein and high-density lipoprotein particle subclasses predict coronary events and are favorably changed by gemfibrozil therapy in the Veterans Affairs High-Density Lipoprotein Intervention Trial. | Circulation 20060328 |
| Cardioprotective properties of fibrates: which fibrate, which patients, what mechanism? | Circulation 20060328 |
| Biological evaluation of 1-alkyl-3-phenylthioureas as orally active HDL-elevating agents. | Bioorganic & medicinal chemistry letters 20060101 |
| Glucuronidation converts gemfibrozil to a potent, metabolism-dependent inhibitor of CYP2C8: implications for drug-drug interactions. | Drug metabolism and disposition: the biological fate of chemicals 20060101 |
| Statin/fibrate combination in patients with metabolic syndrome or diabetes: evaluating the risks of pharmacokinetic drug interactions. | Expert opinion on drug safety 20060101 |
| Clinical inquiries. What are effective medication combinations for dyslipidemia? | The Journal of family practice 20060101 |
| Comparison of isocaloric very low carbohydrate/high saturated fat and high carbohydrate/low saturated fat diets on body composition and cardiovascular risk. | Nutrition & metabolism 20060101 |
| Fibrates in combination with statins in the management of dyslipidemia. | Journal of clinical hypertension (Greenwich, Conn.) 20060101 |
| Effective use of combination lipid therapy. | Current atherosclerosis reports 20060101 |
| Mode of action of fibrates in the regulation of triglyceride and HDL-cholesterol metabolism. | Drugs of today (Barcelona, Spain : 1998) 20060101 |
| Drug-induced hepatitis in a patient with malignant melanoma treated with interferon alfa 2b adjuvantly who had been administered gemfibrozil in therapy. | Medical oncology (Northwood, London, England) 20060101 |
| [A case of interstitial lung disease with atorvastatin (Tahor) and a review of the literature about these effects observed under statins]. | Therapie 20060101 |
| [Early use of gemfibrozil in patients with non ST Elevation acute coronary syndrome. Changes of markers of inflammation and von Willebrand factor]. | Kardiologiia 20060101 |
| Atherogenic dyslipidemia in metabolic syndrome and type 2 diabetes: therapeutic options beyond statins. | Cardiovascular diabetology 20060101 |
| Genetic polymorphisms of MMP1, MMP3 and MMP7 gene promoter and risk of colorectal adenoma. | BMC cancer 20060101 |
| Comparison of effects of fibrates in patients with hypertriglyceridemia. | Advances in therapy 20060101 |
| Tamoxifen-induced severe hypertriglyceridaemia and acute pancreatitis. | Clinical drug investigation 20060101 |
| Severe combined hyperlipidaemia and retinal lipid infiltration in a patient with Type 2 diabetes mellitus. | Lipids in health and disease 20060101 |
| Chinese red yeast rice (Monascus purpureus) for primary hyperlipidemia: a meta-analysis of randomized controlled trials. | Chinese medicine 20060101 |
| Lipid-modifying and pleiotropic effects of gemfibrozil, simvastatin and pravastatin in patients with dyslipidemia. | Folia medica 20060101 |
| Combination of a sterol absorption inhibitor and cardiovascular agents for the treatment of dyslipidemia. | Recent patents on cardiovascular drug discovery 20060101 |
| K-111: the emerging evidence for its potential in the treatment of the metabolic syndrome. | Core evidence 20060101 |
| Effect of gemfibrozil on the pharmacokinetics of pioglitazone. | European journal of clinical pharmacology 20051201 |
| Potential drug-drug interaction between interferon alfa-2b and gemfibrozil in a patient with malignant melanoma. | Clinical therapeutics 20051201 |
| Optimal lipid modification: the rationale for combination therapy. | Vascular health and risk management 20051201 |
| Fibrates inhibit aldose reductase activity in the forward and reverse reactions. | Biochemical pharmacology 20051125 |
| Statins and PPARalpha agonists induce myotoxicity in differentiated rat skeletal muscle cultures but do not exhibit synergy with co-treatment. | Toxicology and applied pharmacology 20051101 |
| 2nd International Symposium on Triglycerides and HDL: lipid abnormalities and their treatment. | Diabetes care 20051101 |
| Gemfibrozil reduces small low-density lipoprotein more in normolipemic subjects classified as low-density lipoprotein pattern B compared with pattern A. | The American journal of cardiology 20051101 |
| Effective use of combination lipid therapy. | Current cardiology reports 20051101 |
| Differential associations of statin and fibrate treatment with carotid arterial remodeling. | American journal of hypertension 20051101 |
| The forgotten majority: unfinished business in cardiovascular risk reduction. | Journal of the American College of Cardiology 20051004 |
| Joint Nordic prospective study on human herpesvirus 8 and multiple myeloma risk. | British journal of cancer 20051003 |
| High-density lipoprotein cholesterol: ready for prime time? | Singapore medical journal 20051001 |
| Patients with low levels of high-density lipoprotein cholesterol: to treat or not to treat? | Singapore medical journal 20051001 |
| Metabolism of repaglinide by CYP2C8 and CYP3A4 in vitro: effect of fibrates and rifampicin. | Basic & clinical pharmacology & toxicology 20051001 |
| Protective effect of coenzyme Q10 in simvastatin and gemfibrozil induced rhabdomyolysis in rats. | Indian journal of experimental biology 20051001 |
| [Drug combinations: statins and fibrates]. | Arquivos brasileiros de cardiologia 20051001 |
| Enantiomeric separation of gemfibrozil chiral analogues by capillary electrophoresis with heptakis(2,3,6-tri-O-methyl)-beta-cyclodextrin as chiral selector. | Journal of chromatography. A 20050923 |
| What is the most effective strategy for managing diabetic dyslipidaemia? | Atherosclerosis. Supplements 20050901 |
| Fate of endocrine-disruptor, pharmaceutical, and personal care product chemicals during simulated drinking water treatment processes. | Environmental science & technology 20050901 |
| A teleost in vitro reporter gene assay to screen for agonists of the peroxisome proliferator-activated receptors. | Environmental toxicology and chemistry 20050901 |
| Actions of calcium channel blockers on vascular proteoglycan synthesis: relationship to atherosclerosis. | Vascular health and risk management 20050901 |
| Vascular endothelium as a target of beraprost sodium and fenofibrate for antiatherosclerotic therapy in type 2 diabetes mellitus. | Vascular health and risk management 20050901 |
| Agonists for the peroxisome proliferator-activated receptor-alpha and the retinoid X receptor inhibit inflammatory responses of microglia. | Journal of neuroscience research 20050801 |
| The effects of multiple doses of fenofibrate on the pharmacokinetics of pravastatin and its 3alpha-hydroxy isomeric metabolite. | Journal of clinical pharmacology 20050801 |
| Coadministration of gemfibrozil and itraconazole has only a minor effect on the pharmacokinetics of the CYP2C9 and CYP3A4 substrate nateglinide. | British journal of clinical pharmacology 20050801 |
| Rifampin markedly decreases and gemfibrozil increases the plasma concentrations of atorvastatin and its metabolites. | Clinical pharmacology and therapeutics 20050801 |
| PPARs as targets for metabolic and cardiovascular diseases. | Mini reviews in medicinal chemistry 20050801 |
| Comparison between duration dependent effects of Simvastatin and Gemfibrozil on dyslipidemia in patients with type 2 diabetes. | JPMA. The Journal of the Pakistan Medical Association 20050801 |
| Occurrence and fate of pharmaceutically active compounds in the environment, a case study: Höje River in Sweden. | Journal of hazardous materials 20050715 |
| Low high-density lipoprotein cholesterol disorders and cardiovascular risk: contribution of associated low-density lipoprotein subclass abnormalities. | Current opinion in cardiology 20050701 |
| Cholesterol levels and statin use in patients with coronary heart disease treated in primary care settings. | Preventing chronic disease 20050701 |
| Different response of senescent female Sprague-Dawley rats to gemfibrozil and rosiglitazone administration. | Experimental gerontology 20050701 |
| Interconversion pharmacokinetics of simvastatin and its hydroxy acid in dogs: effects of gemfibrozil. | Pharmaceutical research 20050701 |
| Effects of fibrates on human organic anion-transporting polypeptide 1B1-, multidrug resistance protein 2- and P-glycoprotein-mediated transport. | Xenobiotica; the fate of foreign compounds in biological systems 20050701 |
| The human lipid regulator, gemfibrozil bioconcentrates and reduces testosterone in the goldfish, Carassius auratus. | Aquatic toxicology (Amsterdam, Netherlands) 20050601 |
| Relative impact of CYP3A genotype and concomitant medication on the severity of atorvastatin-induced muscle damage. | Pharmacogenetics and genomics 20050601 |
| Antiatherogenic properties of fibrates. | Arteriosclerosis, thrombosis, and vascular biology 20050601 |
| A case of hypothyroidism and type 2 diabetes associated with type V hyperlipoproteinemia and eruptive xanthomas. | Journal of Korean medical science 20050601 |
| Gateways to clinical trials. | Methods and findings in experimental and clinical pharmacology 20050601 |
| Photodegradation of common environmental pharmaceuticals and estrogens in river water. | Environmental toxicology and chemistry 20050601 |
| Synthesis of fenoprofen and gemfibrozil styrene-maleic acid copolymer conjugates. | Acta pharmaceutica (Zagreb, Croatia) 20050601 |
| Efficacy and safety of rosuvastatin in treatment of dyslipidemia. | American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists 20050515 |
| The role of lipid management in diabetes. | Cardiology clinics 20050501 |
| Effects of gemfibrozil, itraconazole, and their combination on the pharmacokinetics of pioglitazone. | Clinical pharmacology and therapeutics 20050501 |
| [Lipid therapy in risk patients. Do we concentrate too much on LDL cholesterol?]. | MMW Fortschritte der Medizin 20050407 |
| Effect of gemfibrozil on the pharmacokinetics and pharmacodynamics of racemic warfarin in healthy subjects. | British journal of clinical pharmacology 20050401 |
| Human pharmaceuticals, hormones, and personal care product ingredients in runoff from agricultural fields irrigated with treated wastewater. | Journal of agricultural and food chemistry 20050309 |
| Regulation of human apoA-I by gemfibrozil and fenofibrate through selective peroxisome proliferator-activated receptor alpha modulation. | Arteriosclerosis, thrombosis, and vascular biology 20050301 |
| Ongoing clinical trials of the pleiotropic effects of statins. | Vascular health and risk management 20050301 |
| 1-Hydroxyalkyl-3-phenylthioureas as novel HDL-elevating agents. | Bioorganic & medicinal chemistry letters 20050201 |
| Effects of switching pravastatin to cerivastatin on C-reactive protein, butyrylcholinesterase, and lipids. | Current medical research and opinion 20050201 |
| Summaries for patients. Targeting cholesterol treatment toward increasing high-density lipoprotein levels. | Annals of internal medicine 20050118 |
| A randomized trial of a strategy for increasing high-density lipoprotein cholesterol levels: effects on progression of coronary heart disease and clinical events. | Annals of internal medicine 20050118 |
| Comparative effects of rosuvastatin and gemfibrozil on glucose, insulin, and lipid metabolism in insulin-resistant, nondiabetic patients with combined dyslipidemia. | The American journal of cardiology 20050115 |
| De novo synthesis of diacylglycerol in endothelium may mediate the association between PAI-1 and the insulin resistance syndrome. | Medical hypotheses 20050101 |
| Reporting rate of rhabdomyolysis with fenofibrate + statin versus gemfibrozil + any statin. | The American journal of cardiology 20050101 |
| The sialic acid content of fibrinogen decreases during pregnancy and increases in response to fibrate therapy. | Thrombosis research 20050101 |
| Changes in lipids over twelve months after initiating protease inhibitor therapy among persons treated for HIV/AIDS. | Lipids in health and disease 20050101 |
| Cost effectiveness of treating low HDL-cholesterol in the primary prevention of coronary heart disease. | PharmacoEconomics 20050101 |
| Comparative effects of fibrates on drug metabolizing enzymes in human hepatocytes. | Pharmaceutical research 20050101 |
| Peroxisome proliferator-activated receptors (PPAR) agonists affect cell viability, apoptosis and expression of cell cycle related proteins in cell lines of glial brain tumors. | Neoplasma 20050101 |
| Study of the liquid chromatography retention of some fibrate-type antihyperlipidemic drugs on C18 and CN columns: application for quantitation in pharmaceutical formulations. | Journal of AOAC International 20050101 |
| Ezetimibe: a review of its metabolism, pharmacokinetics and drug interactions. | Clinical pharmacokinetics 20050101 |
| Statins research unfinished saga: desirability versus feasibility. | Cardiovascular diabetology 20050101 |
| Drug interactions of clinical importance with antihyperglycaemic agents: an update. | Drug safety 20050101 |
| A two-dimensional electrophoresis preliminary approach to human hepatocarcinoma differentiation induced by PPAR-agonists. | Journal of cellular and molecular medicine 20050101 |
| Comparative bioavailability study with two gemfibrozil tablet formulations in healthy volunteers. | Arzneimittel-Forschung 20050101 |
| Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) study: baseline characteristics and short-term effects of fenofibrate [ISRCTN64783481]. | Cardiovascular diabetology 20050101 |
| A new perspective in the treatment of dyslipidemia : can fenofibrate offer unique benefits in the treatment of type 2 diabetes mellitus? | Treatments in endocrinology 20050101 |
| Beyond low-density lipoprotein: addressing the atherogenic lipid triad in type 2 diabetes mellitus and the metabolic syndrome. | American journal of cardiovascular drugs : drugs, devices, and other interventions 20050101 |
| Association of common variation in the PPARA gene with incident myocardial infarction in individuals with type 2 diabetes: a Go-DARTS study. | Nuclear receptor 20050101 |
| [Preparation and investigation of gemfibrozil + dimethyl-beta-cyclodextrin products and solid dosage forms]. | Acta pharmaceutica Hungarica 20050101 |
| Determination of fenofibrate and gemfibrozil in pharmaceuticals by densitometric and videodensitometric thin-layer chromatography. | Journal of AOAC International 20050101 |
| [Withdrawal of cerivastatin revealed a flaw of post-marketing surveillance system in the United States]. | Kokuritsu Iyakuhin Shokuhin Eisei Kenkyujo hokoku = Bulletin of National Institute of Health Sciences 20050101 |
| Simvastatin: a review. | Expert opinion on pharmacotherapy 20041201 |
| Potential for conflict of interest in the evaluation of suspected adverse drug reactions: use of cerivastatin and risk of rhabdomyolysis. | JAMA 20041201 |
| Potential for conflict of interest in the evaluation of suspected adverse drug reactions: a counterpoint. | JAMA 20041201 |
| Bayer's response to 'potential for conflict of interest in the evaluation of suspected adverse drug reactions: use of cerivastatin and risk of rhabdomyolysis'. | JAMA 20041201 |
| Pharmacologic treatment of type 2 diabetic dyslipidemia. | Pharmacotherapy 20041201 |
| Regulation of phase I and phase II steroid metabolism enzymes by PPAR alpha activators. | Toxicology 20041115 |
| R643G polymorphism in PECAM-1 influences transendothelial migration of monocytes and is associated with progression of CHD and CHD events. | Atherosclerosis 20041101 |
| Effect of gemfibrozil on change in renal function in men with moderate chronic renal insufficiency and coronary disease. | American journal of kidney diseases : the official journal of the National Kidney Foundation 20041101 |
| Predictors of change in low-density lipoprotein size during lipid-lowering treatment in type 2 diabetes. | Metabolism: clinical and experimental 20041101 |
| Dysregulation of growth hormone in acquired generalized lipodystrophy. | Saudi medical journal 20041101 |
| Gene expression analysis of peroxisome proliferators- and phenytoin-induced hepatotoxicity using cDNA microarray. | The Journal of veterinary medical science 20041101 |
| PPARalpha activators down-regulate CYP2C7, a retinoic acid and testosterone hydroxylase. | Toxicology 20041015 |
| Gemfibrozil and its glucuronide inhibit the organic anion transporting polypeptide 2 (OATP2/OATP1B1:SLC21A6)-mediated hepatic uptake and CYP2C8-mediated metabolism of cerivastatin: analysis of the mechanism of the clinically relevant drug-drug interaction between cerivastatin and gemfibrozil. | The Journal of pharmacology and experimental therapeutics 20041001 |
| Polymorphisms in the gene encoding lipoprotein lipase in men with low HDL-C and coronary heart disease: the Veterans Affairs HDL Intervention Trial. | Journal of lipid research 20041001 |
| Management of hypertriglyceridemia in patients receiving interferon for malignant melanoma. | The Annals of pharmacotherapy 20041001 |
| Prevention of age-related changes in rat cortex transcription factor activator protein-1 by hypolipidemic drugs. | Biochemical pharmacology 20041001 |
| Risk of adverse events with fibrates. | The American journal of cardiology 20041001 |
| Nevirapine and efavirenz elicit different changes in lipid profiles in antiretroviral-therapy-naive patients infected with HIV-1. | PLoS medicine 20041001 |
| Management of dyslipidaemia in HIV-infected patients receiving antiretroviral therapy. | Antiviral therapy 20041001 |
| Co-induction of methyltransferase Rv0560c by naphthoquinones and fibric acids suggests attenuation of isoprenoid quinone action in Mycobacterium tuberculosis. | Canadian journal of microbiology 20041001 |
| Gemfibrozil for secondary prevention of cardiovascular events in mild to moderate chronic renal insufficiency. | Kidney international 20040901 |
| Occurrence and fate of pharmaceuticals and alkylphenol ethoxylate metabolites in an effluent-dominated river and wetland. | Environmental toxicology and chemistry 20040901 |
| Assessment of a multiple-dose drug interaction between ezetimibe, a novel selective cholesterol absorption inhibitor and gemfibrozil. | International journal of clinical pharmacology and therapeutics 20040901 |
| PPARalpha agonists stimulate progastrin production in human colorectal carcinoma cells. | Regulatory peptides 20040815 |
| Targeted inactivation of cystic fibrosis transmembrane conductance regulator chloride channel gene prevents ischemic preconditioning in isolated mouse heart. | Circulation 20040810 |
| Treatment of hyperlipidemia in cardiac transplant recipients. | American heart journal 20040801 |
| Association between different lipid-lowering treatment strategies and blood pressure control in the Brisighella Heart Study. | American heart journal 20040801 |
| Characterisation of cerivastatin as a P-glycoprotein substrate: studies in P-glycoprotein-expressing cell monolayers and mdr1a/b knock-out mice. | Naunyn-Schmiedeberg's archives of pharmacology 20040801 |
| [Alcoholic and non-alcoholic steatohepatitis]. | Therapeutische Umschau. Revue therapeutique 20040801 |
| PPARalpha agonists clofibrate and gemfibrozil inhibit cell growth, down-regulate hCG and up-regulate progesterone secretions in immortalized human trophoblast cells. | Biochemical pharmacology 20040715 |
| Mitochondrial respiratory chain dysfunction, a non-receptor-mediated effect of synthetic PPAR-ligands: biochemical and pharmacological implications. | Biochemical and biophysical research communications 20040702 |
| Rhabdomyolysis with HMG-CoA reductase inhibitors and gemfibrozil combination therapy. | Pharmacoepidemiology and drug safety 20040701 |
| Safety of statins: focus on clinical pharmacokinetics and drug interactions. | Circulation 20040615 |
| Rhabdomyolysis associated with hydroxymethylglutaryl-coenzyme A reductase inhibitors. | American heart journal 20040601 |
| How doubling up drugs saves lives. Why doctors increasingly deploy an array of medications all at once. | Heart advisor 20040601 |
| Prevention of cardiovascular events in diabetes. | Clinical evidence 20040601 |
| Peroxisome proliferator-activated receptors and atherogenesis: regulators of gene expression in vascular cells. | Circulation research 20040514 |
| Peroxisome proliferator-activated receptor alpha agonists as therapy for autoimmune disease. | Journal of immunology (Baltimore, Md. : 1950) 20040501 |
| Triglycerides induce leptin resistance at the blood-brain barrier. | Diabetes 20040501 |
| The effect of gemfibrozil on the pharmacokinetics of rosuvastatin. | Clinical pharmacology and therapeutics 20040501 |
| [Effects of Shenshuai Yangzhen capsule on lipid metabolism disorder in rats with chronic renal failure]. | Di 1 jun yi da xue xue bao = Academic journal of the first medical college of PLA 20040501 |
| APOA5 gene variants, lipoprotein particle distribution, and progression of coronary heart disease: results from the LOCAT study. | Journal of lipid research 20040401 |
| Effects of PPARgamma and PPARalpha agonists on serum leptin levels in diet-induced obese rats. | Hormone and metabolic research = Hormon- und Stoffwechselforschung = Hormones et metabolisme 20040401 |
| The influence of buffer composition on tissue integrity during permeability experiments 'in vitro'. | International journal of pharmaceutics 20040319 |
| The effect of fibrates and other lipid-lowering drugs on plasma homocysteine levels. | Expert opinion on drug safety 20040301 |
| Fibrates modify the expression of key factors involved in bile-acid synthesis and biliary-lipid secretion in gallstone patients. | European journal of clinical pharmacology 20040201 |
| Early detection of drug interactions utilizing a computerized drug prescription handling system-focus on cerivastatin-gemfibrozil. | European journal of clinical pharmacology 20040201 |
| Rhabdomyolysis and renal failure associated with gemfibrozil monotherapy. | The Annals of pharmacotherapy 20040201 |
| Effects of gemfibrozil treatment on vascular reactivity of streptozotocin-diabetic rat aorta. | The Journal of pharmacy and pharmacology 20040201 |
| Serum homocysteine concentrations, gemfibrozil treatment, and progression of coronary atherosclerosis. | Atherosclerosis 20040201 |
| Effect of fibrates on postprandial remnant-like particles in patients with combined hyperlipidemia. | Atherosclerosis 20040201 |
| Influence of lipid lowering fibrates on P-glycoprotein activity in vitro. | Biochemical pharmacology 20040115 |
| Fibrates for treatment of the metabolic syndrome. | Current atherosclerosis reports 20040101 |
| Lack of hypotriglyceridemic effect of gemfibrozil as a consequence of age-related changes in rat liver PPARalpha. | Biochemical pharmacology 20040101 |
| Statin treatment and the natural history of atherosclerotic-related diseases: pathogenic mechanisms and the risk-benefit profile. | Current pharmaceutical design 20040101 |
| An ounce of prevention. Drugs used to treat hyperlipidemia (Part 1). | Orthopedic nursing 20040101 |
| Role of fibrates in reducing coronary risk: a UK Consensus. | Current medical research and opinion 20040101 |
| The effect of alcohol and gemfibrozil co-administration in Wistar rats. | In vivo (Athens, Greece) 20040101 |
| Rising statin use and effect on ischemic stroke outcome. | BMC medicine 20040101 |
| Patient with gemfibrozil-controlled hypertriglyceridemia that developed acute pancreatitis after starting ketogenic diet. | Current surgery 20040101 |
| Repaglinide : a pharmacoeconomic review of its use in type 2 diabetes mellitus. | PharmacoEconomics 20040101 |
| [Fibrates: mechanism of action, effect on levels of lipids and lipoproteins, risk of coronary events. Part 1. Clofibrate, gemfibrosil, besafibrate]. | Kardiologiia 20040101 |
| Treatment of hyperlipidemia in elderly persons with exercise training, nonpharmacologic therapy, and drug combinations. | The American journal of geriatric cardiology 20040101 |
| [Cell protection through PPAR nuclear receptor activation]. | Therapie 20040101 |
| Application of UV-derivative spectra for determination of four antihyperlipidaemic drugs in pharmaceutical formulations. | Acta poloniae pharmaceutica 20040101 |
| Ciprofibrate therapy in patients with hypertriglyceridemia and low high density lipoprotein (HDL)-cholesterol: greater reduction of non-HDL cholesterol in subjects with excess body weight (The CIPROAMLAT study). | Cardiovascular diabetology 20040101 |
| Effect of gemfibrozil on the metabolism of pitavastatin--determining the best animal model for human CYP and UGT activities. | Drug metabolism and drug interactions 20040101 |
| Disparities in lipid management for African Americans and Caucasians with coronary artery disease: a national cross-sectional study. | BMC cardiovascular disorders 20040101 |
| Significance of high density lipoprotein-cholesterol in cardiovascular risk prevention: recommendations of the HDL Forum. | American journal of cardiovascular drugs : drugs, devices, and other interventions 20040101 |
| Emphysematous cystitis: an unusual disease of the Genito-Urinary system suspected on imaging. | Annals of clinical microbiology and antimicrobials 20040101 |
| Removal of selected non-steroidal anti-inflammatory drugs (NSAIDs), gemfibrozil, carbamazepine, beta-blockers, trimethoprim and triclosan in conventional wastewater treatment plants in five EU countries and their discharge to the aquatic environment. | Water science and technology : a journal of the International Association on Water Pollution Research 20040101 |
| The need for a large-scale trial of fibrate therapy in diabetes: the rationale and design of the Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) study. [ISRCTN64783481]. | Cardiovascular diabetology 20040101 |
| Which is the best lipid-modifying strategy in metabolic syndrome and diabetes: fibrates, statins or both? | Cardiovascular diabetology 20040101 |
| Determination of acidic pharmaceuticals, antibiotics and ivermectin in river sediment using liquid chromatography-tandem mass spectrometry. | Journal of chromatography. A 20031222 |
| HIV protease inhibitor ritonavir induces lipoatrophy in male mice. | AIDS research and human retroviruses 20031201 |
| Occurrence of neutral and acidic drugs in the effluents of Canadian sewage treatment plants. | Environmental toxicology and chemistry 20031201 |
| Measurement of diacylglycerol acyltransferase activity in isolated hepatocytes. | Analytical biochemistry 20031115 |
| Possible differences between fibrates in pharmacokinetic interactions with statins. | Archives of internal medicine 20031027 |
| Gemfibrozil increases the specific binding of rat-cortex nuclear extracts to a PPRE probe. | Life sciences 20031024 |
| Identification and prediction of promiscuous aggregating inhibitors among known drugs. | Journal of medicinal chemistry 20031009 |
| Gemfibrozil considerably increases the plasma concentrations of rosiglitazone. | Diabetologia 20031001 |
| Effects of baseline level of triglycerides on changes in lipid levels from combined fluvastatin + fibrate (bezafibrate, fenofibrate, or gemfibrozil). | The American journal of cardiology 20031001 |
| Metabolism and disposition of gemfibrozil in Wistar and multidrug resistance-associated protein 2-deficient TR- rats. | Xenobiotica; the fate of foreign compounds in biological systems 20031001 |
| The effects of the phytoestrogenic isoflavone genistein on the hepatic disposition of preformed and hepatically generated gemfibrozil 1-O-acyl glucuronide in the isolated perfused rat liver. | The Journal of pharmacy and pharmacology 20031001 |
| Effects of metformin or gemfibrozil on the lipodystrophy of HIV-infected patients receiving protease inhibitors. | Antiviral therapy 20031001 |
| Lipid-lowering drugs and serum liver enzymes: the effects of body weight and baseline enzyme levels. | Fundamental & clinical pharmacology 20030801 |
| Antibodies to human heat shock protein 60, hypertension and dyslipidemia. A study of joint effects on coronary risk. | Atherosclerosis 20030801 |
| Subcutaneous cholesterol nodules: a case report. | Joint, bone, spine : revue du rhumatisme 20030801 |
| Effects of peroxisome proliferators gemfibrozil and clofibrate on syntheses of dolichol and cholesterol in rat liver. | Journal of biochemistry 20030801 |
| Sensitive method for the quantitative determination of gemfibrozil in dog plasma by liquid-liquid cartridge extraction and liquid chromatography-tandem mass spectrometry. | Journal of chromatography. B, Analytical technologies in the biomedical and life sciences 20030705 |
| Efficacy of atorvastatin and gemfibrozil, alone and in low dose combination, in the treatment of diabetic dyslipidemia. | The Journal of clinical endocrinology and metabolism 20030701 |
| Therapeutic implications of recent ATP III guidelines and the important role of combination therapy in total dyslipidemia management. | Current opinion in cardiology 20030701 |
| Emerging importance of HDL cholesterol in developing high-risk coronary plaques in acute coronary syndromes. | Current opinion in cardiology 20030701 |
| Cardioprotective activity of synthetic guggulsterone (E and Z-isomers) in isoproterenol induced myocardial ischemia in rats: A comparative study. | Indian journal of clinical biochemistry : IJCB 20030701 |
| Minireview: lipid metabolism, metabolic diseases, and peroxisome proliferator-activated receptors. | Endocrinology 20030601 |
| Managing lipid disorders: further evaluation of the VA-HIT. | Current diabetes reports 20030601 |
| Combination lipid-lowering therapy in diabetes. | Current diabetes reports 20030601 |
| An observational study of severe hypertriglyceridemia, hypertriglyceridemic acute pancreatitis, and failure of triglyceride-lowering therapy when estrogens are given to women with and without familial hypertriglyceridemia. | Clinica chimica acta; international journal of clinical chemistry 20030601 |
| Commentary. Secondary causes of hypertriglyceridemia and pancreatitis. | Clinica chimica acta; international journal of clinical chemistry 20030601 |
| Gemfibrozil reduces release of tumor necrosis factor-alpha in peripheral blood mononuclear cells from healthy subjects and patients with coronary heart disease. | Clinica chimica acta; international journal of clinical chemistry 20030601 |
| Gemfibrozil increases plasma pravastatin concentrations and reduces pravastatin renal clearance. | Clinical pharmacology and therapeutics 20030601 |
| Fibrates and their newly synthesized glycinate or glycinate-methylester derivatives: comparison of the interactions with liver cytochrome P450 dependent monooxygenase- and oxidase-functions in vitro. | Experimental and toxicologic pathology : official journal of the Gesellschaft fur Toxikologische Pathologie 20030601 |
| Reverse cholesterol transport, high density lipoproteins and HDL cholesterol: recent data. | Diabetes & metabolism 20030601 |
| Influence of P-glycoprotein and MRP efflux pump inhibitors on the intracellular activity of azithromycin and ciprofloxacin in macrophages infected by Listeria monocytogenes or Staphylococcus aureus. | The Journal of antimicrobial chemotherapy 20030501 |
| Insulin resistance and cardiovascular events with low HDL cholesterol: the Veterans Affairs HDL Intervention Trial (VA-HIT). | Diabetes care 20030501 |
| A novel functional polymorphism in the PECAM-1 gene (53G>A) is associated with progression of atherosclerosis in the LOCAT and REGRESS studies. | Atherosclerosis 20030501 |
| Current best treatment for non-alcoholic fatty liver disease. | Expert opinion on pharmacotherapy 20030501 |
| Preparation of antiserum against rat delta6-desaturase and its use to evaluate the desaturase protein levels in rats treated with gemfibrozil, a ligand for peroxisome proliferator-activated receptor alpha. | Bioscience, biotechnology, and biochemistry 20030501 |
| Polarised transport of monocarboxylic acid type drugs across rat jejunum in vitro: the effect of mucolysis and ATP-depletion. | International journal of pharmaceutics 20030430 |
| Statins and fibrates for the treatment of hyperlipidaemia in HIV-infected patients receiving HAART. | AIDS (London, England) 20030411 |
| Progression of atherosclerosis is associated with variation in the alpha1-antitrypsin gene. | Arteriosclerosis, thrombosis, and vascular biology 20030401 |
| Gemfibrozil reduces plasma C-reactive protein levels in abdominally obese men with the atherogenic dyslipidemia of the metabolic syndrome. | Arteriosclerosis, thrombosis, and vascular biology 20030401 |
| Cell handling, membrane-binding properties, and membrane-penetration modeling approaches of pivampicillin and phthalimidomethylampicillin, two basic esters of ampicillin, in comparison with chloroquine and azithromycin. | Pharmaceutical research 20030401 |
| Differential effects of lipid-lowering therapies on stroke prevention: a meta-analysis of randomized trials. | Archives of internal medicine 20030324 |
| [Antilipemic therapy and rhabdomyolysis]. | Orvosi hetilap 20030316 |
| Opposing mechanisms of NADPH-cytochrome P450 oxidoreductase regulation by peroxisome proliferators. | Biochemical pharmacology 20030315 |
| Spectrofluorimetric and micelle-enhanced spectrofluorimetric methods for the determination of gemfibrozil in pharmaceutical preparations. | Journal of pharmaceutical and biomedical analysis 20030310 |
| Effects of hypolipidemic treatment on serum markers of vascular inflammation in dyslipidemic men. | Medical science monitor : international medical journal of experimental and clinical research 20030301 |
| Cell-specific toxicity of fibrates in human embryonal rhabdomyosarcoma cells. | Naunyn-Schmiedeberg's archives of pharmacology 20030301 |
| Self-micellization of gemfibrozil 1-O-beta acyl glucuronide in aqueous solution. | Pharmaceutical research 20030301 |
| Effects of gemfibrozil, itraconazole, and their combination on the pharmacokinetics and pharmacodynamics of repaglinide: potentially hazardous interaction between gemfibrozil and repaglinide. | Diabetologia 20030301 |
| HDL in atherosclerosis: actor or bystander? | Atherosclerosis. Supplements 20030301 |
| Frequency of creatine kinase elevation during treatment with fluvastatin in combination with fibrates (bezafibrate, fenofibrate, or gemfibrozil). | The American journal of cardiology 20030115 |
| Myoglobinuria and COX deficiency in a patient taking cerivastatin and gemfibrozil. | Neurology 20030114 |
| Fenofibrate-induced hyperhomocysteinaemia: clinical implications and management. | Drug safety 20030101 |
| Acute rhabdomyolysis after gemfibrozil therapy in a pregnant patient complicated with acute pancreatitis and hypertriglycerdemia while receiving continuous veno-venous hemofiltration therapy. | Renal failure 20030101 |
| Prevalence of antilipemic drug use in Taiwan: analysis of a sampling cohort within the national health insurance. | Journal of the Chinese Medical Association : JCMA 20030101 |
| Melanoma chemoprevention: a role for statins or fibrates? | American journal of therapeutics 20030101 |
| Use of a quadrupole linear ion trap mass spectrometer in metabolite identification and bioanalysis. | Rapid communications in mass spectrometry : RCM 20030101 |
| Cardiovascular complications of diabetes: prevention and management. | Clinical cornerstone 20030101 |
| Statin-fibrate combination: therapy for hyperlipidemia: a review. | Current medical research and opinion 20030101 |
| [Antilipemics: results of large studies]. | Therapie 20030101 |
| [Drug interactions with antilipemics]. | Therapie 20030101 |
| Metabolic syndrome and type 2 diabetes mellitus: focus on peroxisome proliferator activated receptors (PPAR). | Cardiovascular diabetology 20030101 |
| Recombinant apolipoprotein A-I(Milano): a novel agent for the induction of regression of atherosclerotic plaques. | Annals of medicine 20030101 |
| The sense of coherence, occupation and all-cause mortality in the Helsinki Heart Study. | European journal of epidemiology 20030101 |
| [Renal dyslipidemia in patients on chronic hemodialysis]. | Lijecnicki vjesnik 20030101 |
| Beneficial effects of fish liver preparations of sea bass (Lates calcarifer) versus gemfibrozil in high fat diet-induced lipid-intolerant rats. | Journal of medicinal food 20030101 |
| Clinical pharmacokinetics of atorvastatin. | Clinical pharmacokinetics 20030101 |
| Pharmacological comparison of the statins. | Arzneimittel-Forschung 20030101 |
| [Drug safety. Notes regarding drug surveillance]. | Farmacia hospitalaria : organo oficial de expresion cientifica de la Sociedad Espanola de Farmacia Hospitalaria 20030101 |
| Effectiveness of statin-gemfibrozil combination therapy in patients with mixed hyperlipidemia: experience of a community lipid clinic and safety review from the literature. | Preventive cardiology 20030101 |
| Overview of pharmacologic therapy for the treatment of dyslipidemia. | Journal of managed care pharmacy : JMCP 20030101 |
| Studies on the interaction between fibrates and statins using human hepatic microsomes. | Arzneimittel-Forschung 20030101 |
| Interaction between fibrates and statins--metabolic interactions with gemfibrozil. | Drug metabolism and drug interactions 20030101 |
| Combination therapy with an HMG-CoA reductase inhibitor and a fibric acid derivative: a critical review of potential benefits and drawbacks. | American journal of cardiovascular drugs : drugs, devices, and other interventions 20030101 |
| Optimal therapy of low levels of high density lipoprotein-cholesterol. | American journal of cardiovascular drugs : drugs, devices, and other interventions 20030101 |
| Statins in hypercholesterolaemia: a dose-specific meta-analysis of lipid changes in randomised, double blind trials. | BMC family practice 20030101 |
| Pharmacoeconomic aspects of patients treated by hemodialysis. | Bratislavske lekarske listy 20030101 |
| Effects of gemfibrozil conversion to fenofibrate on lipids in patients on statin therapy. | The American journal of cardiology 20021215 |
| Gemfibrozil inhibits CYP2C8-mediated cerivastatin metabolism in human liver microsomes. | Drug metabolism and disposition: the biological fate of chemicals 20021201 |
| HDL and triglyceride as therapeutic targets. | Current opinion in lipidology 20021201 |
| Lipid-lowering therapy in people with type 2 diabetes. | Current opinion in lipidology 20021201 |
| Role of lipid-modifying therapy in the prevention of initial and recurrent stroke. | Current opinion in lipidology 20021201 |
| Gemfibrozil encapsulation and release from microspheres and macromolecular conjugates. | European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences 20021201 |
| Diabetes, plasma insulin, and cardiovascular disease: subgroup analysis from the Department of Veterans Affairs high-density lipoprotein intervention trial (VA-HIT). | Archives of internal medicine 20021201 |
| Comparison of gemfibrozil and fenofibrate in patients with dyslipidemic coronary heart disease. | Pharmacotherapy 20021201 |
| Gemfibrozil greatly increases plasma concentrations of cerivastatin. | Clinical pharmacology and therapeutics 20021201 |
| Fibrate treatment does not modify the expression of acyl coenzyme A oxidase in human liver. | Clinical pharmacology and therapeutics 20021201 |
| High rates of adverse effects and patient unawareness of withdrawn lipid-lowering drug combination in a public hospital clinic. | Pharmacoepidemiology and drug safety 20021201 |
| Fenofibrate in the treatment of dyslipidemia: a review of the data as they relate to the new suprabioavailable tablet formulation. | Clinical therapeutics 20021201 |
| Gemfibrozil, a lipid-lowering drug, inhibits the induction of nitric-oxide synthase in human astrocytes. | The Journal of biological chemistry 20021129 |
| A randomized, double-blind study of gemfibrozil for the treatment of protease inhibitor-associated hypertriglyceridaemia. | AIDS (London, England) 20021108 |
| Effects of various fibrates on serum alkaline phosphatase activity. | Atherosclerosis 20021101 |
| Effects of fibrates on metabolism of statins in human hepatocytes. | Drug metabolism and disposition: the biological fate of chemicals 20021101 |
| Rhabdomyolysis associated with gemfibrozil-colchicine therapy. | The Annals of pharmacotherapy 20021101 |
| Optimizing bexarotene therapy for cutaneous T-cell lymphoma. | Journal of the American Academy of Dermatology 20021101 |
| Effect of gemfibrozil on apolipoprotein B secretion and diacylglycerol acyltransferase activity in human hepatoblastoma (HepG2) cells. | Atherosclerosis 20021001 |
| Comparison in patients with type 2 diabetes of fibric acid versus hepatic hydroxymethyl glutaryl-coenzyme a reductase inhibitor treatment of combined dyslipidemia. | Metabolism: clinical and experimental 20021001 |
| Treatment of non-alcoholic steatohepatitis. | Best practice & research. Clinical gastroenterology 20021001 |
| Thiourea-based gemfibrozil analogues as HDL-elevating agents. | Bioorganic & medicinal chemistry letters 20020902 |
| Cerivastatin and gemfibrozil-induced cardiac rhabdomyolysis. | The American journal of forensic medicine and pathology 20020901 |
| Peroxisome proliferators do not activate the transcription factors AP-1, early growth response-1, or heat shock factors 1 and 2 in rats or hamsters. | Toxicological sciences : an official journal of the Society of Toxicology 20020901 |
| A safety look at currently available statins. | Expert opinion on drug safety 20020901 |
| Rat liver acyl-CoA synthetase 4 is a peripheral-membrane protein located in two distinct subcellular organelles, peroxisomes, and mitochondrial-associated membrane. | Archives of biochemistry and biophysics 20020815 |
| Gemfibrozil lowers plasma lipids and increases polyunsaturated fatty acid content and oxidative susceptibility of lipoproteins in hypertriglyceridemia. | Clinica chimica acta; international journal of clinical chemistry 20020801 |
| Severe rhabdomyolysis related to cerivastatin without gemfibrozil. | Annals of internal medicine 20020702 |
| Effect of albumin and cytosol on enzyme kinetics of tolbutamide hydroxylation and on inhibition of CYP2C9 by gemfibrozil in human liver microsomes. | The Journal of pharmacology and experimental therapeutics 20020701 |
| Rhabdomyolysis-related renal tubular damage studied by proton nuclear magnetic resonance spectroscopy of urine. | Clinical chemistry 20020701 |
| Cholesteryl ester transfer protein TaqI B2B2 genotype is associated with higher HDL cholesterol levels and lower risk of coronary heart disease end points in men with HDL deficiency: Veterans Affairs HDL Cholesterol Intervention Trial. | Arteriosclerosis, thrombosis, and vascular biology 20020701 |
| Influence of the angiotensin-converting enzyme gene insertion/deletion polymorphism on lipoprotein/lipid response to gemfibrozil. | Clinical genetics 20020701 |
| Peroxisome proliferator-activated receptor agonists, hyperlipidaemia, and atherosclerosis. | Pharmacology & therapeutics 20020701 |
| Ligand and coactivator recruitment preferences of peroxisome proliferator activated receptor alpha. | The Journal of steroid biochemistry and molecular biology 20020701 |
| Detection of pharmaceutical contaminations of river, pond, and tap water from Cologne (Germany) and surroundings. | International journal of hygiene and environmental health 20020701 |
| Treatment of dyslipidaemia in high-risk patients: too little, too late. | International journal of clinical practice. Supplement 20020701 |
| Coenzyme Q10 and cardiovascular disease: a review. | The Journal of cardiovascular nursing 20020701 |
| Gene expression analysis reveals chemical-specific profiles. | Toxicological sciences : an official journal of the Society of Toxicology 20020601 |
| Prediction of compound signature using high density gene expression profiling. | Toxicological sciences : an official journal of the Society of Toxicology 20020601 |
| Mechanistic studies on metabolic interactions between gemfibrozil and statins. | The Journal of pharmacology and experimental therapeutics 20020601 |
| Asymptomatic acute pancreatitis due to tamoxifen-induced severe hypertriglyceridemia in a patient with diabetes mellitus and breast cancer. | Journal of chemotherapy (Florence, Italy) 20020601 |
| [Metabolic modifications related to immunosuppressive drugs]. | Revue medicale de Bruxelles 20020601 |
| Computational selection of distinct class- and subclass-specific gene expression signatures. | Journal of biomedical informatics 20020601 |
| Myopathy Associated With HMG-CoA Reductase Inhibitors (Statins): A Series of 10 Patients and Review of the Literature. | Journal of clinical neuromuscular disease 20020601 |
| Effects of a lipid lowering fibrate and hormone replacement therapy on serum lipids and lipoproteins in overweight postmenopausal women with elevated triglycerides. | Maturitas 20020520 |
| Differential effects of gemfibrozil on migration, proliferation and proteoglycan production in human vascular smooth muscle cells. | Atherosclerosis 20020501 |
| A comparison of pravastatin and gemfibrozil in the treatment of dyslipoproteinemia in patients with non-insulin-dependent diabetes mellitus. | Atherosclerosis 20020501 |
| Rhabdomyolysis after concomitant use of cyclosporine, simvastatin, gemfibrozil, and itraconazole. | The Annals of pharmacotherapy 20020501 |
| Stroke prevention: management of modifiable vascular risk factors. | Journal of neurology 20020501 |
| Possible mechanisms of the fibrate-induced increase in serum creatinine. | Clinical nephrology 20020501 |
| Postprandial lipemia--effect of lipid-lowering drugs. | Atherosclerosis. Supplements 20020501 |
| Effects of gemfibrozil on insulin resistance to fat metabolism in subjects with type 2 diabetes and hypertriglyceridaemia. | Diabetes, obesity & metabolism 20020501 |
| Analysis of acidic drugs in the effluents of sewage treatment plants using liquid chromatography-electrospray ionization tandem mass spectrometry. | Journal of chromatography. A 20020405 |
| Fibrate-induced increase in serum urea and creatinine levels. | Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association 20020401 |
| Severe rhabdomyolysis and cerivastatin-gemfibrozil combination therapy. | The Annals of pharmacotherapy 20020401 |
| A new reality: achieving cholesterol-lowering goals in clinical practice. | Atherosclerosis. Supplements 20020401 |
| Gateways to Clinical Trials. | Methods and findings in experimental and clinical pharmacology 20020401 |
| Peroxisome proliferator-activated receptor alpha gene variants influence progression of coronary atherosclerosis and risk of coronary artery disease. | Circulation 20020326 |
| Synthesis and antiplatelet activity of gemfibrozil chiral analogues. | Bioorganic & medicinal chemistry letters 20020311 |
| Myopathy and rhabdomyolysis with lipid-lowering drugs. | Toxicology letters 20020310 |
| Are high-density lipoprotein and triglyceride levels important in secondary prevention: impressions from the BIP and VA-HIT trials. | International journal of cardiology 20020301 |
| Analysis of serious adverse events. Lipid-lowering therapy revisited. | Canadian family physician Medecin de famille canadien 20020301 |
| Successful pregnancy outcome in a patient with severe chylomicronemia due to compound heterozygosity for mutant lipoprotein lipase. | Clinical biochemistry 20020301 |
| Statin stories. | Diabetes, obesity & metabolism 20020301 |
| Rhabdomyolysis associated with cerivastatin plus gemfibrozil combined regimen. | The British journal of general practice : the journal of the Royal College of General Practitioners 20020301 |
| Therapy and clinical trials. | Current opinion in lipidology 20020201 |
| The study on a PVC membrane electrode for gemfibrozil. | Biological & pharmaceutical bulletin 20020201 |
| Severe hypertriglyceridemia and pancreatitis following hormone replacement prior to cryothaw transfer. | Journal of assisted reproduction and genetics 20020201 |
| Atorvastatin versus four statin-fibrate combinations in patients with familial combined hyperlipidaemia. | Journal of cardiovascular risk 20020201 |
| Cost-effectiveness of gemfibrozil for coronary heart disease patients with low levels of high-density lipoprotein cholesterol: the Department of Veterans Affairs High-Density Lipoprotein Cholesterol Intervention Trial. | Archives of internal medicine 20020128 |
| Sexual dysfunction secondary to gemfibrozil. | Pharmacotherapy 20020101 |
| LDL-cholesterol lowering effect of a generic product of simvastatin compared to simvastatin (Zocor) in Thai hypercholesterolemic subjects -- a randomized crossover study, the first report from Thailand. | BMC clinical pharmacology 20020101 |
| Effect of peroxisome proliferators on the methylation and protein level of the c-myc protooncogene in B6C3F1 mice liver. | Journal of biochemical and molecular toxicology 20020101 |
| The effects of gemfibrozil on hyperlipidemia in children with persistent nephrotic syndrome. | The Turkish journal of pediatrics 20020101 |
| Use of fibrates in the management of hyperlipidemia in HIV-infected patients receiving HAART. | Infection 20020101 |
| Fenofibrate of gemfibrozil for treatment of types IIa and IIb primary hyperlipoproteinemia: a randomized, double-blind, crossover study. | Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists 20020101 |
| Beyond LDL-C--the importance of raising HDL-C. | Current medical research and opinion 20020101 |
| Recurrent hypoglycaemic episodes in a patient with Type 2 diabetes under fibrate therapy. | Journal of diabetes and its complications 20020101 |
| Lipids in end-stage renal disease. | Journal of nephrology 20020101 |
| Effect of ciprofibrate on C-reactive protein and fibrinogen levels. | Angiology 20020101 |
| Pharmacokinetic-pharmacodynamic drug interactions with HMG-CoA reductase inhibitors. | Clinical pharmacokinetics 20020101 |
| Lipid-lowering drugs: are adverse effects predictable and reversible? | Cardiology 20020101 |
| Pharmacologic therapy of lipid disorders in the elderly. | The American journal of geriatric cardiology 20020101 |
| Results of use of metformin and replacement of starch with saturated fat in diets of patients with type 2 diabetes. | Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists 20020101 |
| Combination of gemfibrozil and orlistat for treatment of combined hyperlipidemia with predominant hypertriglyceridemia. | Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists 20020101 |
| [Rhabdomyolysis, acute renal failure and use of cerivastatin combined with gemfibrozil. New evidence]. | Nefrologia : publicacion oficial de la Sociedad Espanola Nefrologia 20020101 |
| Influences of the PPAR alpha-L162V polymorphism on plasma HDL(2)-cholesterol response of abdominally obese men treated with gemfibrozil. | Genetics in medicine : official journal of the American College of Medical Genetics 20020101 |
| Micronised fenofibrate: an updated review of its clinical efficacy in the management of dyslipidaemia. | Drugs 20020101 |
| Fate of pharmaceuticals during indirect potable reuse. | Water science and technology : a journal of the International Association on Water Pollution Research 20020101 |
| Low serum levels of high-density lipoprotein cholesterol and hypolipidaemic treatment. | Current medical research and opinion 20020101 |
| Effects of fibrates on serum metabolic parameters. | Current medical research and opinion 20020101 |
| HMG CoA reductase-inhibitor-related myopathy and the influence of drug interactions. | Internal medicine journal 20020101 |
| Rhabdomyolysis from the combination of a statin and gemfibrozil: an uncommon but serious adverse reaction. | WMJ : official publication of the State Medical Society of Wisconsin 20020101 |
| A multidisciplinary program for achieving lipid goals in chronic hemodialysis patients. | BMC nephrology 20020101 |
| Ezetimibe: the first in a novel class of selective cholesterol-absorption inhibitors. | Heart disease (Hagerstown, Md.) 20020101 |
| The anatomy of a clinical trial. The West of Scotland Coronary Prevention Study. | Medical principles and practice : international journal of the Kuwait University, Health Science Centre 20020101 |
| Strategies for minimizing hyperlipidemia after cardiac transplantation. | American journal of cardiovascular drugs : drugs, devices, and other interventions 20020101 |
| Management of protease inhibitor-associated hyperlipidemia. | American journal of cardiovascular drugs : drugs, devices, and other interventions 20020101 |
| Micronized fenofibrate in dyslipidemia: a focus on plasma high-density lipoprotein cholesterol (HDL-C) levels. | American journal of cardiovascular drugs : drugs, devices, and other interventions 20020101 |
| Treatment of nonalcoholic fatty liver disease. | Annals of hepatology 20020101 |
| [Myopathy with rhabdomyolysis as an adverse effect of simultaneous treatment with cerivastatin and gemfibrozil]. | Lijecnicki vjesnik 20020101 |
| Targeting low high-density lipoprotein cholesterol for therapy: lessons from the Veterans Affairs High-density Lipoprotein Intervention Trial. | The American journal of cardiology 20011220 |
| Determination of drugs in surface water and wastewater samples by liquid chromatography-mass spectrometry: methods and preliminary results including toxicity studies with Vibrio fischeri. | Journal of chromatography. A 20011214 |
| Rhabdomyolysis with HMG CoA reductase inhibitors: a class effect? | Journal of clinical pharmacy and therapeutics 20011201 |
| Treatment for the procoagulant state in type 2 diabetes. | Endocrinology and metabolism clinics of North America 20011201 |
| Massive rhabdomyolysis and life threatening hyperkalaemia in a patient with the combination of cerivastatin and gemfibrozil. | Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association 20011201 |
| [Lipid-lowering drugs]. | Nihon yakurigaku zasshi. Folia pharmacologica Japonica 20011201 |
| [Rhabdomyolysis associated with combined treatment of cerivastatin and gemfibrozil]. | Revista clinica espanola 20011201 |
| Eruptive xanthomas. | Dermatology online journal 20011201 |
| Effects of fenofibrate and gemfibrozil on plasma homocysteine. | Lancet (London, England) 20011124 |
| Effects of fenofibrate and gemfibrozil on plasma homocysteine. | Lancet (London, England) 20011124 |
| Intercalation and controlled release of pharmaceutically active compounds from a layered double hydroxide. | Chemical communications (Cambridge, England) 20011121 |
| Statin-associated myopathy. | The Medical journal of Australia 20011105 |
| Gemfibrozil is a potent inhibitor of human cytochrome P450 2C9. | Drug metabolism and disposition: the biological fate of chemicals 20011101 |
| Are high density lipoprotein (HDL) and triglyceride levels relevant in stroke prevention? | Cardiovascular research 20011101 |
| Gemfibrozil increases paraoxonase activity in type 2 diabetic patients. A new hypothesis of the beneficial action of fibrates? | Diabetes & metabolism 20011101 |
| Niacin, but not gemfibrozil, selectively increases LP-AI, a cardioprotective subfraction of HDL, in patients with low HDL cholesterol. | Arteriosclerosis, thrombosis, and vascular biology 20011101 |
| Clinical inquiries. What laboratory monitoring is appropriate to detect adverse drug reactions in patients on cholesterol-lowering agents? | The Journal of family practice 20011101 |
| PPARS, metabolic disease and atherosclerosis. | Pharmacological research 20011101 |
| Ciprofibrate versus gemfibrozil in the treatment of mixed hyperlipidemias: an open-label, multicenter study. | Metabolism: clinical and experimental 20011101 |
| Effect of gemfibrozil on the pharmacokinetics and pharmacodynamics of glimepiride. | Clinical pharmacology and therapeutics 20011101 |
| Effect of trans-dehydrocrotonin, a 19-nor-clerodane diterpene from Croton cajucara on experimental hypertriglyceridaemia and hypercholesterolaemia induced by Triton WR 1339 (tyloxapol) in mice. | Planta medica 20011101 |
| Attenuation by fibrates of plasminogen activator inhibitor type-1 expression in human arterial smooth muscle cells. | Thrombosis and haemostasis 20011101 |
| [Cerivastatin and gemfibrozil: a dangerous combination]. | Atencion primaria 20011015 |
| Cyclic nucleotides in platelets of genetically hypertriglyceridemic and hypertensive rats. Thrombin and nitric oxide responses are unrelated to plasma triglyceride levels. | Thrombosis research 20011001 |
| Serum magnesium status during lipid-lowering drug treatment in non-insulin-dependent diabetic patients. | Metabolism: clinical and experimental 20011001 |
| Fatal rhabdomyolysis caused by lipid-lowering therapy. | Southern medical journal 20011001 |
| Increase in hepatic expression of SREBP-2 by gemfibrozil administration to rats. | Biochemical pharmacology 20010915 |
| [Severe rhabdomyolysis associated with cerivastatin and gemfibrozil]. | Medicina clinica 20010915 |
| Bayer pulls cerivastatin (Baycol) from market. | CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne 20010904 |
| New developments in the prevention of atherosclerosis in patients with low high-density lipoprotein cholesterol. | Current atherosclerosis reports 20010901 |
| Is the relationship between adipose tissue and waist girth altered by weight loss in obese men? | Obesity research 20010901 |
| Smoking diminishes the beneficial effect of statins: observations from the landmark trials. | Angiology 20010901 |
| Cerivastatin and gemfibrozil-associated rhabdomyolysis. | The Annals of pharmacotherapy 20010901 |
| [Cholestatic hepatitis caused by gemfibrozil]. | Revista espanola de enfermedades digestivas : organo oficial de la Sociedad Espanola de Patologia Digestiva 20010901 |
| Molecular basis for the effect of lipid lowering drugs on growth factors after de-endothelialization. | Chinese medical journal 20010901 |
| Statin safety. | Nursing standard (Royal College of Nursing (Great Britain) : 1987) 20010901 |
| Altered expression of the carboxylesterases ES-4 and ES-10 by peroxisome proliferator chemicals. | Toxicology 20010828 |
| Baycol withdrawn from market. | Circulation 20010821 |
| Bayer decides to withdraw cholesterol lowering drug. | BMJ (Clinical research ed.) 20010818 |
| A sensitive method for the determination of gemfibrozil in human plasma samples by RP-LC. | Journal of pharmaceutical and biomedical analysis 20010801 |
| PPARalpha-dependent induction of liver microsomal esterification of estradiol and testosterone by a prototypical peroxisome proliferator. | Endocrinology 20010801 |
| Gemfibrozil treatment potentiates oxidative resistance of high-density lipoprotein in hypertriglyceridemic patients. | European journal of clinical investigation 20010801 |
| Effect of a six month gemfibrozil treatment and dietary recommendations on the metabolic risk profile of visceral obese men. | International journal of obesity and related metabolic disorders : journal of the International Association for the Study of Obesity 20010801 |
| Inhibitory action of gemfibrozil on cholesterol absorption in rat intestine. | Journal of lipid research 20010801 |
| [Fatal rhabdomyolysis caused by cerivastatin]. | Revue medicale de Liege 20010801 |
| Rhabdomyolysis and acute renal failure following a switchover of therapy between two fibric acid derivatives. | Singapore medical journal 20010801 |
| The effects of lipid-lowering agents on acute renal allograft rejection. | Transplantation 20010727 |
| Effects of fenofibrate and gemfibrozil on plasma homocysteine. | Lancet (London, England) 20010707 |
| Differential activation of hepatic NF-kappaB in rats and hamsters by the peroxisome proliferators Wy-14,643, gemfibrozil, and dibutyl phthalate. | Toxicological sciences : an official journal of the Society of Toxicology 20010701 |
| Remnant-like lipoprotein particle cholesterol concentration and progression of coronary and vein-graft atherosclerosis in response to gemfibrozil treatment. | Atherosclerosis 20010701 |
| Postprandial remnant-like lipoproteins in hypertriglyceridemia. | The Journal of clinical endocrinology and metabolism 20010701 |
| Fenofibrate and warfarin interaction. | Pharmacotherapy 20010701 |
| Gemfibrozil improves insulin sensitivity and flow-mediated vasodilatation in type 2 diabetic patients. | European journal of clinical investigation 20010701 |
| [Peroxisome proliferator-activated receptors (PPARs) in the vessel wall: new regulators of gene expression in vascular cells]. | Zeitschrift fur Kardiologie 20010701 |
| Gemfibrozil prevents major coronary events by increasing HDL-cholesterol and more. | Expert opinion on pharmacotherapy 20010701 |
| Reduction in stroke with gemfibrozil in men with coronary heart disease and low HDL cholesterol: The Veterans Affairs HDL Intervention Trial (VA-HIT). | Circulation 20010612 |
| Normocholesterolaemic dyslipidaemia: is there a role for fibrates? | The Medical journal of Australia 20010604 |
| Normocholesterolaemic dysslipidaemia: is there a role for fibrates? | The Medical journal of Australia 20010604 |
| Effect of statin versus fibrate on postprandial endothelial dysfunction: role of remnant-like particles. | Cardiovascular research 20010601 |
| Effect of gemfibrozil on the composition and oxidation properties of very-low-density lipoprotein and high-density lipoprotein in patients with hypertriglyceridemia. | The Journal of laboratory and clinical medicine 20010601 |
| Combination therapy with cerivastatin and gemfibrozil causing rhabdomyolysis: is the interaction predictable? | The American journal of medicine 20010601 |
| Fibrate treatment can increase serum creatinine levels. | Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association 20010601 |
| Ciprofibrate versus gemfibrozil in the treatment of mixed hyperlipidemias: an open-label, multicenter study. | Metabolism: clinical and experimental 20010601 |
| Choice of lipid-regulating drugs. | The Medical letter on drugs and therapeutics 20010528 |
| New recommendations from the 1999 American College of Cardiology/American Heart Association acute myocardial infarction guidelines. | The Annals of pharmacotherapy 20010501 |
| Plasma concentrations of active lovastatin acid are markedly increased by gemfibrozil but not by bezafibrate. | Clinical pharmacology and therapeutics 20010501 |
| PPARalpha deficiency reduces insulin resistance and atherosclerosis in apoE-null mice. | The Journal of clinical investigation 20010415 |
| Rhabdomyolysis after cerivastatin-gemfibrozil therapy in an HIV-infected patient with protease inhibitor-related hyperlipidemia. | AIDS (London, England) 20010413 |
| Effects of peroxisome proliferators on antioxidant enzymes and antioxidant vitamins in rats and hamsters. | Toxicological sciences : an official journal of the Society of Toxicology 20010401 |
| Antiviral activity of lovastatin against respiratory syncytial virus in vivo and in vitro. | Antimicrobial agents and chemotherapy 20010401 |
| [Rhabdomyolysis complicated with acute renal insufficiency in a patient treated with gemfibrozil and cerivastatin]. | Revista clinica espanola 20010401 |
| Relation of gemfibrozil treatment and lipid levels with major coronary events: VA-HIT: a randomized controlled trial. | JAMA 20010328 |
| Statin-fibrate combinations in patients with combined hyperlipedemia. | Atherosclerosis 20010301 |
| [Helsinki Heart Study]. | Nihon rinsho. Japanese journal of clinical medicine 20010301 |
| [VA-HIT Study [Veterans Affairs High-Density Lipoprotein Cholesterol Intervention Trial Study]]. | Nihon rinsho. Japanese journal of clinical medicine 20010301 |
| [Gemfibrozil: new aspects in clinical use]. | Nihon rinsho. Japanese journal of clinical medicine 20010301 |
| HMG-CoA Reductase Inhibitor Myopathy: Clinical, Electrophysiological, and Pathologic Data in Five Patients. | Journal of clinical neuromuscular disease 20010301 |
| Effects of peroxisome proliferators on glutathione and glutathione-related enzymes in rats and hamsters. | Toxicology and applied pharmacology 20010215 |
| Evidence for significant differences in microsomal drug glucuronidation by canine and human liver and kidney. | Drug metabolism and disposition: the biological fate of chemicals 20010201 |
| The effects of gemfibrozil upon the metabolism of chylomicron-like emulsions in patients with endogenous hypertriglyceridemia. | Cardiovascular research 20010201 |
| Statins for stroke: the second story? | Circulation 20010123 |
| [The role of HDL in the prevention of cardiovascular events]. | Orvosi hetilap 20010121 |
| Normocholesterolaemic dyslipidaemia: is there a role for fibrates? | The Medical journal of Australia 20010115 |
| Stimulatory effect of clofibrate and gemfibrozil administration on the formation of fatty acid esters of estradiol by rat liver microsomes. | The Journal of pharmacology and experimental therapeutics 20010101 |
| Statins in children: what do we know and what do we need to do? | Current atherosclerosis reports 20010101 |
| The role of fibric acids in atherosclerosis. | Current atherosclerosis reports 20010101 |
| Deterioration in renal function associated with fibrate therapy. | Clinical nephrology 20010101 |
| Short-term gemfibrozil treatment reverses lipid profile and peroxidation but does not alter blood glucose and tissue antioxidant enzymes in chronically diabetic rats. | Molecular and cellular biochemistry 20010101 |
| Treatment of nonalcoholic fatty liver: present and emerging therapies. | Seminars in liver disease 20010101 |
| Treatment of dyslipoproteinemia in the metabolic syndrome. | Experimental and clinical endocrinology & diabetes : official journal, German Society of Endocrinology [and] German Diabetes Association 20010101 |
| Severe rhabdomyolysis associated with the cerivastin-gemfibrozil combination therapy: report of a case. | Texas Heart Institute journal 20010101 |
| Hypertriglyceridemia: a review of clinical relevance and treatment options: focus on cerivastatin. | Current medical research and opinion 20010101 |
| Statin-fibrate combination therapy. | The Annals of pharmacotherapy 20010101 |
| Hypercholesterolemia, lipid-lowering agents, and the risk for brain infarction. | Neurology 20010101 |
| [Fibrates in the secondary prevention of ischemic cardiopathy]. | Archivos de cardiologia de Mexico 20010101 |
| [Rhabdomyolysis and anuric kidney failure induced by the treatment with a gemfibrozil-cerivastatin combination]. | Nefrologia : publicacion oficial de la Sociedad Espanola Nefrologia 20010101 |
| A risk factor for atherosclerosis: triglyceride-rich lipoproteins. | Advances in internal medicine 20010101 |
| Drug treatment of combined hyperlipidemia. | American journal of cardiovascular drugs : drugs, devices, and other interventions 20010101 |
| Fibrate-induced increase in blood urea and creatinine: is gemfibrozil the only innocuous agent? | Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association 20001201 |
| A case with severe rhabdomyolysis and renal failure associated with cerivastatin-gemfibrozil combination therapy--a case report. | Angiology 20000801 |
| Evidence against the peroxisome proliferator-activated receptor alpha (PPARalpha) as the mediator for polyunsaturated fatty acid suppression of hepatic L-pyruvate kinase gene transcription. | Journal of lipid research 20000501 |
| Rhabdomyolysis and acute renal failure after changing statin-fibrate combinations. | Cardiology 20000101 |
| Fibrates, dyslipoproteinaemia and cardiovascular disease. | Current opinion in lipidology 19991201 |
| Effects of fibrate compounds on expression of plasminogen activator inhibitor-1 by cultured endothelial cells. | Arteriosclerosis, thrombosis, and vascular biology 19990601 |
| Rhabdomyolysis and renal failure associated with cerivastatin-gemfibrozil combination therapy. | The American journal of cardiology 19990401 |
| Fibrate-modulated expression of fibrinogen, plasminogen activator inhibitor-1 and apolipoprotein A-I in cultured cynomolgus monkey hepatocytes -- role of the peroxisome proliferator-activated receptor-alpha. | Thrombosis and haemostasis 19981201 |
| [Acute hepatitis caused by gemfibrozil]. | Gastroenterologia y hepatologia 19981001 |
| Atorvastatin and gemfibrozil metabolites, but not the parent drugs, are potent antioxidants against lipoprotein oxidation. | Atherosclerosis 19980601 |
| Effects of two different fibric acid derivatives on lipoproteins, cholesteryl ester transfer, fibrinogen, plasminogen activator inhibitor and paraoxonase activity in type IIb hyperlipoproteinaemia. | Atherosclerosis 19980501 |
| [Gemfibrozil induced impotence]. | Anales de medicina interna (Madrid, Spain : 1984) 19980301 |
| Clinical pharmacokinetics of fibric acid derivatives (fibrates). | Clinical pharmacokinetics 19980201 |
| Rhabdomyolysis associated with simvastatin-gemfibrozil therapy. | Southern medical journal 19970501 |
| Hepatic microsomal enzyme induction, beta-oxidation, and cell proliferation following administration of clofibrate, gemfibrozil, or bezafibrate in the CD rat. | Toxicology and applied pharmacology 19970101 |
| Studies on the mechanism of fibrate-inhibited expression of plasminogen activator inhibitor-1 in cultured hepatocytes from cynomolgus monkey. | Arteriosclerosis, thrombosis, and vascular biology 19970101 |
| A head-to-head comparison of the cost effectiveness of HMG-CoA reductase inhibitors and fibrates in different types of primary hyperlipidemia. | Cardiovascular drugs and therapy 19970101 |
| Peroxisome proliferators alter the expression of estrogen-metabolizing enzymes. | Biochimie 19970101 |
| Opposite effects of bezafibrate and gemfibrozil in both normal and hypertriglyceridemic rats. | Atherosclerosis 19961115 |
| The effects of gemfibrozil upon the hypercoagulable state in dyslipidaemic patients with chronic renal failure. | Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association 19961101 |
| Peroxisome proliferators induce mouse liver stearoyl-CoA desaturase 1 gene expression. | Proceedings of the National Academy of Sciences of the United States of America 19960903 |
| Hepatotumorigenicity and peroxisome proliferation induced by the hypolipidemic CI-924 in a two-year study in male and female B6C3F1 mice. | Toxicologic pathology 19960101 |
| Rhabdomyolysis and acute renal failure associated with gemfibrozil therapy. | Nephron 19960101 |
| Hypolipidemic activity of select fibrates correlates to changes in hepatic apolipoprotein C-III expression: a potential physiologic basis for their mode of action. | Journal of lipid research 19951201 |
| Gemfibrozil-induced peroxisome proliferation and hepatomegaly in male F344 rats. | Cancer letters 19951106 |
| Currently available hypolipidaemic drugs and future therapeutic developments. | Bailliere's clinical endocrinology and metabolism 19951001 |
| Spondylitis-like and symmetric polyarthralgia associated with gemfibrozil therapy. | British journal of rheumatology 19950701 |
| Selective modification of rat hepatic microsomal fatty acid chain elongation and desaturation by fibrates: relationship with peroxisome proliferation. | British journal of pharmacology 19950401 |
| Gemfibrozil induced myositis: a case report with light microscopic and ultrastructural study. | Chinese medical sciences journal = Chung-kuo i hsueh k'o hsueh tsa chih 19940601 |
| [Gemfibrozil-induced myopathy]. | Harefuah 19931101 |
| Rhabdomyolysis and renal failure secondary to combination therapy of hyperlipidemia with lovastatin and gemfibozil. | Connecticut medicine 19930901 |
| Acute compartment syndrome: an unusual presentation of gemfibrozil induced myositis. | The Medical journal of Australia 19930104 |
| Gemfibrozil-induced impotence. | The Annals of pharmacotherapy 19930101 |
| Vasculitis, Raynaud's phenomenon and polyarthritis associated with gemfibrozil therapy. | British journal of rheumatology 19930101 |
| Mechanism of action of fibrates. | Postgraduate medical journal 19930101 |
| Sexual dysfunction after gemfibrozil. | BMJ (Clinical research ed.) 19920919 |
| Gemfibrozil-lovastatin therapy for primary hyperlipoproteinemias. | The American journal of cardiology 19920701 |
| Lovastatin/gemfibrozil myopathy: a clinical, histochemical, and ultrastructural study. | European neurology 19920101 |
| Gemfibrozil-induced myopathy. | Archives of internal medicine 19910901 |
| Cholesterol-lowering agent myopathy (CLAM). | Neurology 19910701 |
| Rhabdomyolysis with simvastatin use. | Nephron 19910101 |
| Effects of gemfibrozil and other fibric acid derivatives on blood lipids and lipoproteins. | Journal of clinical pharmacology 19910101 |
| Gemfibrozil-induced impotence. | Lancet (London, England) 19901103 |
| Myopathy and rhabdomyolysis associated with lovastatin-gemfibrozil combination therapy. | JAMA 19900704 |
| Rhabdomyolysis and acute renal failure induced by combination lovastatin and gemfibrozil therapy. | Annals of internal medicine 19900201 |
| [Headache caused by gemfibrozil]. | Medicina clinica 19900120 |
| Treatment of heterozygous familial hypercholesterolemia with lipid-lowering drugs. | Arteriosclerosis (Dallas, Tex.) 19890101 |
| Gemfibrozil-induced headache. | Lancet (London, England) 19881126 |
| HMG CoA reductase inhibitors. Current clinical experience. | Drugs 19880101 |
Related Products
Featured Products
© 2019 Angene International Limited. All rights Reserved.